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Childhood maltreatment is a key risk factor for poor mental and physical health. Recently, 
variation in epigenetic processes, such as DNA methylation, has emerged as a potential 
pathway mediating this association; yet, the extent to which different forms of maltreatment 
may be characterized by unique vs shared epigenetic signatures is currently unknown. In this 
study, we quantified DNA methylation across the genome in buccal epithelial cell samples 
from a high-risk sample of inner-city youth (n = 124; age = 16-24; 53% female), 68% of 
whom reported experiencing at least one form of maltreatment while growing up. Our 
analyses aimed to identify methylomic variation associated with exposure to five major types 
of childhood maltreatment. We found that: (i) maltreatment types differ in the extent to which 
they associate with methylomic variation, with physical exposures showing the strongest 
associations; (ii) many of the identified loci are annotated to genes previously implicated in 
stress-related outcomes, including psychiatric and physical disorders (e.g. GABBR1, 
GRIN2D, CACNA2D4, PSEN2); and (iii) based on gene ontology analyses, maltreatment 
types not only show unique methylation patterns enriched for specific biological processes 
(e.g. physical abuse and cardiovascular function), but also share a ‘common’ epigenetic 
signature enriched for biological processes related to neural development and organismal 
growth. A stringent set of sensitivity analyses were also run to identify high-confidence 
associations. Together, findings lend novel insights into epigenetic signatures of childhood 
abuse and neglect, point to novel potential biomarkers for future investigation and support a 
molecular link between maltreatment and poor health outcomes. Nevertheless, it will be 
important in future to replicate findings, as the use of cross-sectional data and high rates of 
polyvictimization in our study make it difficult to fully disentangle the shared vs unique 
epigenetic signatures of maltreatment types. Furthermore, studies will be needed to test the 
role of potential moderators in the identified associations, including age of onset and 
chronicity of maltreatment exposure.  




















Childhood maltreatment, encompassing abuse and neglect, is a major public health concern 
that continues to affect up to one in four children worldwide, with often devastating 
developmental consequences (WHO, 2014). Children who experience maltreatment are at 
increased risk for a range of psychiatric problems, including anxiety, depression, post-
traumatic stress, and antisocial behaviour (Cicchetti and Toth, 2005). The effects of 
maltreatment can extend well into adulthood, compromising relationship quality, economic 
productivity and physical health (Danese et al., 2009).  
The theory of latent vulnerability proposes that maltreatment exposure calibrates a 
range of biological and neurocognitive systems in line with a threatening and unpredictable 
early environment (McCrory and Viding, 2015). While potentially adaptive in the short term, 
such changes can increase vulnerability in the long term. Consistent with this view, numerous 
biological correlates of maltreatment have now been identified, including accelerated cellular 
ageing, neuroendocrine dysregulation, heightened inflammatory response as well as altered 
brain structure and function (Danese et al., 2011, McCrory et al., 2012, Shalev et al., 2013). 
Recent evidence indicates that, as well as affecting common biological pathways, different 
forms of maltreatment may also exert unique effects. For example, while abuse has been 
associated with changes in neural circuitry underlying threat processing, neglect has been 
associated with biological adaptations to low-complexity environments (Sheridan and 
McLaughlin, 2014).  
A key challenge for current research is to understand how, at a molecular level, these 
environmental exposures are translated into phenotypic variation. Epigenetic processes, such 
as DNA methylation (DNAm), which control the functional regulation of gene expression are 
of particular interest in this regard, as mounting evidence suggests they can be modified by 
environmental factors (Jaenisch and Bird, 2003). For example, animal studies have found that 
a number of environmental stressors, such as poor maternal care, induce stable alterations in 
DNAm in the regulatory regions of several HPA axis genes (e.g. the glucocorticoid receptor), 
which in turn influence responses to future stressors (Turecki and Meaney, 2014). Similarly, 
a small number of human studies have documented a link between childhood maltreatment 
and aberrant DNAm in genes important for stress-response, immune function and 
neurodevelopment (Lutz and Turecki, 2014). DNAm has also been shown to regulate a wide 
range of neurobiological processes, including neurogenesis, synaptic plasticity, learning and 
memory (Baker-Andresen et al., 2013, Day et al., 2013) and aberrations in DNAm have been 
observed in a range of diseased states, including stress-related psychiatric disorders such as 
post-traumatic stress and major depression (Bergman and Cedar, 2013, Klengel et al., 2014).   
To date, most epigenetic studies of maltreatment have focused on variation in the 
vicinity of a limited set of pre-selected candidate genes (i.e. GR, FKBP5, BDNF and 5-HTT) 
(Lutz and Turecki, 2014). As such, little is known about the broader effect of maltreatment on 
DNAm across the genome. This is a substantial limitation in light of the fact that 
maltreatment impacts multiple aspects of functioning, across psychological, physical, and 
social domains. Furthermore, existing studies have primarily examined global maltreatment 
(Labonte et al., 2012, Prados et al., 2015, Suderman et al., 2014, Yang et al., 2013), so that 
the extent to which different maltreatment types may have common vs distinct epigenetic 
signatures is unclear. To address these outstanding questions, we explored the relationship 
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between DNAm and five types of maltreatment in a sample of high-risk youth, using 
genome-wide DNAm data drawn from buccal epithelial cells.  
 
Methods and Materials 
Participants 
The current sample was recruited as part of a larger study examining the effects of 
developmental adversity on individual functioning (n = 204, age range = 16-24 years). 
Analyses only included participants for whom DNAm data was available (n = 124). Youth 
from deprived inner London areas were recruited through multiple channels including inner-
city colleges, internet websites and a charity providing services and support to self-referred 
youth. The sample was 53% female and ethnically diverse (49% White, 33% Black, 18% 
other). The study was carried out in accordance with the latest version of the Declaration of 
Helsinki. The study design was reviewed and approved by the UCL Research Ethics 
Committee (ID No: 2462/001) and all participants provided informed consent prior to 
participation, after the nature of the procedures had been fully explained. Further details of 
the sample and recruitment procedures are available elsewhere (Cecil et al., 2014).  
Measures 
Childhood maltreatment – Childhood maltreatment was assessed using the 28-item, self-
report Childhood Trauma Questionnaire (CTQ; Bernstein and Fink, 1998). The CTQ screens 
for experiences of maltreatment “while growing up” and comprises of 5 continuous 
subscales: emotional abuse, sexual abuse, physical abuse, emotional neglect and physical 
neglect. The scales show high internal consistency in our sample ( = .70 – .97). For 
descriptive purposes only, we also classified participants as having experienced maltreatment 
(i.e. yes/no) if they scored above the ‘Low’ threshold specified by the CTQ manual for at 
least one maltreatment type. By including ‘I currently feel unsafe at home’ as an additional 
yes/no item we were able to ascertain that none of the participants in the study were currently 
vulnerable to violence in the domestic environment (e.g. by family or partner). As such, the 
present study investigates the effects of childhood (i.e. past) maltreatment. 
DNA methylation – DNA was extracted from buccal epithelial cells using procedures 
described in Freeman et al. (2003). 500ng of high molecular weight DNA was subjected to 
sodium bisulfite conversion using the EZ-DNA methylation kit (Zymo Research, Orange, 
CA, USA) using the manufacturers standard protocol. DNAm was quantified using the 
Illumina HumanMethylation450 BeadChip (Illumina, USA) with arrays scanned using an 
Illumina iScan (software version 3.3.28). The Illumina 450K array interrogates >485,000 
probes covering 99% of Reference Sequence (RefSeq) genes, with an average of 17 CpG 
sites per gene region. As the samples were run in a single batch, there was no need for batch 
correction. To account for potential chip and position effects, we randomized sample chip 
allocation and placement on the chip. Initial data quality control was conducted using 
GenomeStudio (version 2011.1) to determine the status of staining, extension, hybridization, 
target removal, bisulfite conversion, specificity, non-polymorphic and negative controls. 
Samples that survived this stage were checked for concordance between their reported and 
assessed sex and then quantile normalised using the dasen function within the wateRmelon 
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package (wateRmelon_1.0.3; Pidsley et al., 2013) in R. Probes were removed if they were 
cross-reactive, polymorphic, used for sample identification on the array, had a SNP at the 
single base extension with a minor allele frequency larger than 5% (i.e. common 
polymorphisms) or were located on the Y chromosome, leaving a total of 413,239 probes 
(Chen et al., 2013; Price et al., 2013). DNAm levels are indexed by beta values (ratio of 
methylated signal divided by the sum of the methylated and unmethylated signal, M/M+U). 
Data Analysis 
All analyses were performed within the R statistical environment (version 3.0.1). Methylation 
data was regressed for sex, age and self-reported ethnicity to account for potential 
confounding effects (Liang and Cookson, 2014). The analysis proceeded in three steps. First, 
we ran five independent epigenome-wide association analyses – one for each maltreatment 
type measured – using linear regression models. Probes were considered significant if they 
survived a False Discovery Rate (FDR) correction of q < 0.05. Only maltreatment types that 
were associated with at least one FDR-corrected probe were carried forward to the next step. 
Second, we identified which probes were most consistently associated with all types of 
maltreatment, by ranking them in order of average standardized effect size. Third, we 
examined enriched biological pathways for genes that were associated only with one type of 
maltreatment vs those that were associated with all maltreatment types, using an optimized 
gene ontology method that controls for a range of potential confounds, including background 
probe distribution and gene size (see OS1 for details). More specifically, genes were 
considered ‘unique’ if the probes annotated to them were specifically associated with one 
maltreatment type and none other (i.e. p<0.005 with one type of maltreatment, and p>0.05 
with the other two types of maltreatment). Conversely, genes were considered ‘shared’ if 
probes annotated to them were associated across maltreatment types (p<0.05 consistently 
across all three forms of maltreatment). To calculate statistical power to detect effects, we 
used the pwr package with a p-value threshold of 1.00E-06 to reach 80% power (Tsai & Bell, 
2015) in the context of a linear regression model. Results showed that, with a sample size of 
124 individuals, we could expect to detect an effect size of ≥ 0.32, indicating that the study is 
appropriately powered for detecting medium-to-large effects. 
 
Results  
Descriptives and correlations between study variables shown in Table 1. Based on the CTQ 
cut-off, the majority of youth in the current study reported having experienced at least one 
form of maltreatment while growing up (68%; n = 84). The reported experiences were often 
severe: 75% of physically abused youth were left with bruises or marks as a result of injuries; 
50% of sexually abused youth reported being threatened; and 60% of physically neglected 
youth reported not having enough to eat. Poly-victimization was common, with 74% of 
maltreated youth reporting two or more forms of maltreatment, consistent with previous 
studies (Radford et al., 2011).  
********************************** Table 1********************************* 
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Maltreatment types differ in the extent to which they associate with DNAm variation 
We first examined associations between DNAm across the genome and individual 
maltreatment types (measured continuously). No probes were identified as being 
differentially methylated at a FDR<0.05 for emotional abuse and emotional neglect (OS2); as 
such, these two types of maltreatment were excluded from further analysis. With regards to 
other maltreatment types, the number of differentially methylated probes (DMPs) was: 34 for 
physical abuse, 7 for sexual abuse, and 118 for physical neglect. The 10 top-ranked DMPs for 
each of these maltreatment types are displayed in Table 2 (see OS3 for a complete table of 
FDR-corrected probes). Associations between DNAm and each maltreatment type are 
graphically represented in Figure 1A (see OS4 for quantile-quantile plots for each analysis).  
Physical abuse: The top-ranked DMP, cg20000641, was significantly hypermethylated with 
increased exposure to physical abuse (p=3.54E-11, q=1.47E-05; Table 2A, Figure 1B). This 
probe is located in the promoter region of PSEN2, a gene encoding a presenilin enzyme 
involved in amyloid precursor protein processing that is robustly implicated in Alzheimer’s 
disease (O’Brien and Wong, 2011). Two top-ranked probes were annotated to SMC1A 
(cg02353937: p = 2.90E-09, q=7.89E-04; cg22311608: p = 8.45E-08, q=0.01), a gene 
involved in chromosomal maintenance and DNA repair (Kim et al., 2002). Also of interest 
were DMPs annotated to genes highly expressed in the brain, including SHC2 (cg19736040: 
p = 1.38E-06, q=0.05), involved in neurotrophin-activated Trk receptor signaling within 
cortical neurons and synaptic plasticity in the hippocampus (Epa et al., 2004), and IMPACT 
(cg03013329: p = 2.10E-06, q=0.05), encoding a protein that facilitates neurite outgrowth 
and modulates kinase activation in neurons (Roffe et al., 2013).  
Sexual abuse: The top-ranked DMP associated with sexual abuse (cg17106653, p=4.16E-09, 
q=1.72E-03; Table 2B, Figure 1B) was located in the promoter region of the glutamate 
receptor GRIN2D, a gene implicated in CNS plasticity and excitatory synaptic transmission 
(Traynelis et al., 2010). Other annotated genes of interest include MGMT (cg26528551: p = 
6.84E-08, q=0.01) implicated in DNA repair mechanisms and DIP2C (cg23983710: p = 
5.83E-07, q=0.03), a gene primarily expressed in the brain but whose biological function is 
poorly understood.  
Physical Neglect: The top-ranked DMP associated with physical neglect was cg00691266 in 
EVPN (p=1.01E-07, q=0.01; Table 2C), encoding a protein involved in epidermal growth. 
Several probes were annotated to genes related to brain function, including SYNJ2 
(cg27083825: p = 1.02E-07, q=0.01; Figure 1B), involved in nervous system development 
and neuronal vesicle uncoating (Montesinos et al., 2005); and GABBR1 (cg18116160: p = 
4.01E-07, q = 0.02) a GABA class B receptor important for inhibitory synaptic transmission 
(Kumar et al., 2013). Probes annotated to genes involved in histone regulation were also 
identified, including SETDB1 (cg17918089: p = 1.14E-07, q=0.01), JADE1 (cg09863040: p = 
2.10E-07, q=0.01), and HIST1H1A (cg08054907: p = 5.12E-07, q=0.02).  
Sensitivity analyses: Given that quantile-quantile plots from our epigenome-wide analyses 
indicated skewing of significant results (OS4), we carried out a set of sensitivity analyses to 
test the robustness of the identified associations. First, to minimize the influence of unknown 
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confounders, we ran a surrogate variable analysis (sva package in R; Leek et al., 2012) that 
enabled us to identify unwanted sources of variation in our DNA methylation data. The 
analysis identified 11 surrogate variables representing different sources of variation/noise. 
We then re-ran associations between each form of maltreatment and DNAm additionally 
controlling for these 11 surrogate variables. While variations in significance levels were 
observed across a number of probes (both increases and decreases in p-value), all sites 
remained significantly associated with maltreatment severity (p< 0.05), with the exception of 
two probes related to physical neglect (see OS5). A total of 45 sites (physical abuse: n = 26; 
sexual abuse: n = 7 and physical neglect: n = 12) also survived genome-wide correction (q < 
0.05). Overall, associations with physical and sexual abuse were the least affected by 
unmeasured confounding, and those with physical neglect were the most affected.  
Second, to examine the potential influence of outliers, we applied the winsorize 
function within the robustHD package to the DNAm data and reran epigenome-wide 
analyses, controlling for covariates. The winsorizing method uses censoring rather than 
exclusion, which is preferable with small sample sizes (Sheskin, 2003). Specifically, for each 
probe, values <5% or >95% of the score distribution were transformed to match the closest 
value within this percentile, which enables scores to maintain their relative weight without 
exerting an undue influence on the linear regression model. Although the vast majority of 
associations remained significant after winsorizing (97%; p<0.05), none of the transformed 
DMPs survived genome-wide correction (q>0.05; OS5). It is important to note, however, that 
this sensitivity analysis is highly conservative as it transforms, for each probe, scores at the 
tail ends of the distribution regardless of presence or absence of outliers. As such, this 
approach reduces the range of methylation scores across all probes, resulting in more limited 
variability.  
Third, we performed bootstrapping as a complement to winsorizing using Mplus 
(version 6.1.1; Muthen & Muthen, 2011). Bootstrapping is advantageous with small samples 
as it derives an approximation of the sampling distribution via repeated resampling of the 
available data to yield bias-corrected 95% confidence intervals (CI). Associations were 
considered significant if bootstrapped 95% CIs (10,000 times) did not cross zero. The number 
of DMPs that survived bootstrapping were: n = 29 for physical abuse, n = 1 for sexual abuse, 
and n = 108 for physical neglect. Hence, sites associated with sexual abuse were the most 
affected by this sensitivity analysis, potentially reflecting the low number of individuals 
scoring high on this exposure, resulting in more extreme values. 
Based on the above results, we compiled a list of high-confidence associations (see 
OS5), in order to highlight DMPs that were the most robustly implicated across the three 
sensitivity analyses and as such may be particularly promising candidates for prioritization in 
future studies. High-confidence associations were defined as having (i) an SVA q-value < 
0.05, (ii) a winsorized p-value < 0.05, and (iii) significant bootstrapped 95% CIs. The 
resulting number of high-confidence associations for each exposure were: n = 20 for physical 
abuse, n = 1 for sexual abuse and n = 10 for physical neglect. 
********************************** Table 2********************************* 
********************************** Figure 1********************************* 
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Variability in certain DNAm loci consistently associate with all maltreatment types 
The top 20 hyper- and hypomethylated DMPs consistently associated with all three 
maltreatment types (i.e. physical abuse, sexual abuse and neglect) are shown in Table 3, 
ranked by average standardized effect size. The top-ranked hypermethylated probe, 
cg08796898 (Figure 1C), is located in HUWE1, an important regulator of neural 
proliferation linked to intellectual disability (Vandewalle et al., 2013). Other genes annotated 
to hypermethylated probes include: (i) CACNA2D4 (cg27516159), identified as a shared risk 
locus for multiple psychiatric disorders (Smollen et al., 2013); (ii) WBSCR17 (cg25579180), 
a gene widely expressed in the brain and associated with neurodevelopmental delay 
(Nakamura et al., 2005); (iii) LRP4 (cg12627354), involved in neuromuscular junction 
maintenance and acetylcholine signaling; and (iv) GRB10 (cg26163537), an insulin 
modulator. 
With regard to hypomethylated probes, we identified multiple markers annotated to 
genes that are involved in response to environmental stimuli, including: (i) two probes in 
RPTOR (cg07870603, cg09596252), a gene involved in cell growth regulation in response to 
climatic factors, nutrient and insulin levels (Sun et al., 2010); and (ii) GJD3 (cg22896075), 
which encodes a connexin thought to facilitate environmental adaptation by regulating 
physiological processes such as neuronal excitability (Belousov and Fontes, 2013). Another 
gene, DNAJB6 (cg27496299; Figure 1C), has been found to reduce cellular toxicity and act 
as a molecular chaperone for neuronal proteins, including huntingtin (Mansson et al., 2014). 
Finally, TIAM2 (cg01786585) has been implicated in neurogenesis, particularly in the 
hippocampus, as well as promoting neural migration in the cerebral cortex (Chiu et al., 1999).  
DNAm variation implicates both maltreatment-specific and shared functional pathways 
As a final step, we examined enriched biological pathways for genes that were either (i) 
annotated to DMPs that associated with only one type of maltreatment (p<0.005); or (ii) 
annotated to DMPs that associated with all maltreatment types (p<0.05 across physical abuse, 
sexual abuse and neglect). Following these criteria, neglect showed ‘unique’ epigenetic 
variation in probes annotated to a larger number of genes (n =329) than physical (n =119) and 
sexual abuse (n = 47). A considerable proportion of genes showed epigenetic variation across 
all three maltreatment type (i.e. ‘shared’ genes; n = 2,348; consistent direction of effects).  
Gene ontology analyses were performed for the above sets of genes (except sexual 
abuse, due to the low number of annotated genes), controlling for a range of potential 
confounds, including background probe distribution and gene size (Figure 2; see OS1 for 
details). Results indicated that genes associated with DNAm variation specific to physical 
abuse were enriched for biological processes including cardiovascular function (e.g. cardiac 
muscle hypertrophy, heart rate), fear response, and wound healing (1.04E-12 <p<7.65E-03), 
while those associated with neglect-specific variation were enriched for regulation of 
cholesterol efflux, as well as processes related to cellular function and metabolism (2.91E-11 
<p<1.04E-02; see OS6 for a full list of terms). In contrast, genes associated with epigenetic 
variation shared across maltreatment types were significantly enriched for biological 
processes primarily related to regulation of nervous system development (e.g. neurogenesis, 
glial proliferation, neurotransmitter biosynthesis, oligodendrocyte development) and 
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organismal growth (e.g. organ morphogenesis, negative regulation of growth, response to 
growth factor; see OS7 for a full list of terms; 4.20E-10<p< 1.44E-02).   
********************************** Figure 2********************************* 
Discussion 
 This study is the first to characterize genome-wide DNAm patterns associated with different 
types of childhood abuse and neglect. Strengths include the availability of quantitative data 
on a range of different exposures, the inclusion of a sample of youth featuring high rates of 
adversity, and the analysis of methylome-wide data. Here, we highlight three key findings: (i) 
specific types of maltreatment, particularly physical exposures, are associated with DNAm 
variation at multiple loci; (ii) many of the identified loci are annotated to genes previously 
implicated in psychiatric and medical disorders; and (iii) gene ontology analyses indicate 
that, while maltreatment types show distinct patterns of methylomic variation, they also share 
a common epigenetic ‘signature’ enriched for biological processes related to neural 
development and organismal growth. The use of stringent sensitivity analyses further enabled 
us to identify high-confidence associations, which point to promising candidate loci for 
prioritization in future studies. 
 
Findings lend novel insights into the relationship between maltreatment and DNA 
methylation 
Of the maltreatment types investigated, we found that physical exposures – including 
physical abuse, sexual abuse and physical neglect – all associated with epigenetic variation at 
multiple loci, with neglect showing the largest number of DMPs after genome-wide 
correction (despite having comparable prevalence rates to physical abuse). In contrast, no 
significant loci were identified for emotional abuse and emotional neglect (after multiple 
correction). This was unexpected given that emotional abuse, in particular, has been 
recognized as an important independent predictor of poor individual functioning (Rees, 
2010). Consequently, more work is required to clarify whether results reflect a true lack of 
associations or whether other factors may be at play (e.g. challenges with the 
operationalization of emotional abuse; polyepigenetic effects of smaller magnitude; tissue 
specificity). It is also interesting to note that we identified an unexpectedly high number of 
associations between maltreatment types and DNAm sites located on the X-chromosome. 
Given that sex was controlled for in the analyses, these results suggest that maltreatment 
exposure may influence these DNAm sites similarly for boys and girls. Although sex 
differences were not examined in the present study due to sample size limitations, it will be 
of interest in future to test the potential role of sex in the relationship between maltreatment 
and DNAm.  
Comparability with previous findings on maltreatment and DNAm is limited by the 
fact that, while other epigenetic studies have examined maltreatment as a global construct, we 
investigated DNA methylation profiles associated with specific forms of abuse and neglect. 
As such, a strict test of replication was not possible. Furthermore, past studies have varied 
widely on factors such as choice of tissue (e.g. saliva, blood or brain), DNAm platform (e.g. 
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Illumina 450k vs MeDIP), methodology (e.g. filtering of probes, covariates), maltreatment 
measure (e.g. self-report vs official records), population (e.g. community vs clinical) and 
sample characteristics (e.g. age, sex), making it difficult to assess our findings in the context 
of previous work in the area. 
 Nevertheless, we note here two of the most similar studies to ours, which have also 
used the Illumina 450k platform in peripheral tissues to investigate methylome-wide 
associations with childhood maltreatment. The first study (Yang et al. 2013) used DNA from 
saliva specimens to compare methylomic differences between a sample of maltreated and 
non-maltreated children, using a case-control design. The second study (Prados et al. 2015) 
used blood samples to compare DNAm patterns in adults with borderline personality disorder 
and exposure to high levels of childhood maltreatment vs adults with major depression 
disorder who had experienced low levels of childhood maltreatment (assessed using the same 
measure as our study, the CTQ). Comparing findings from our respective genome-wide 
analyses, we identified one overlapping DNAm site that was associated with maltreatment 
(after genome-wide correction) across both our study and Yang et al.’s (CILP2cg01487433), and 
no overlap with the DNAm sites reported in Prados et al’s study. In addition, we identified 
several overlapping genes between studies (29 with Yang’s et al.’s study; 1 with Prados et 
al.’s study) that had at least one genome-wide significant probe annotated to them. However, 
because these genes varied widely in DNAm probe coverage, it is unclear whether they were 
identified across studies because they robustly associate with maltreatment or because they 
may have had a larger number of DNAm probes annotated to them. As a whole, DMPs were 
found to differ between our study and previous ones. As such, it will be important in future to 
establish whether discrepancies may reflect the examination of global vs individual forms of 
maltreatment, methodological differences between studies or the presence of false positives, 
all issues that should be considered when interpreting the present findings. 
We note that the use of sensitivity analyses in the present study (surrogate variable 
analysis, winsorizing and bootstrapping) enabled us to identify a subset of DMPs that were 
most robustly associated with maltreatment exposure (i.e. ‘high-confidence associations’; n = 
31, 20% of total DMP set), and consequently may show promise as candidate loci for further 
investigation. Of interest, DMPs associated with physical neglect were most affected by the 
surrogate variable analysis, suggesting that the methylomic signature of this maltreatment 
type may in part reflect other sources of variability (e.g. genetic architecture, unmeasured 
exposures, confounding sources). In contrast, DMPs associated with sexual abuse were the 
most affected by the winsorizing and bootstrapping analyses, which may instead reflect the 
low number of individuals reporting high levels of this exposure. In general, associations 
between DNAm and physical abuse were the most robust, with 59% of DMPs (n = 20) 
classified as high-confidence. While these findings may be used in future to inform locus-
prioritization, it is important to note that the identification of high-confidence associations 
was based on a stringent set of criteria, so that the extent to which ‘lower-confidence’ DMPs 
may be robustly associated with maltreatment exposure will still need to be established via 
replication in independent samples.  
 
Epigenetic signatures of maltreatment 
11 
 
The identified DNA methylation markers support a molecular link between maltreatment 
and poor health outcomes 
Our analyses identified multiple DMPs annotated to genes previously associated with 
psychiatric and medical disorders. The top-ranked DMP for physical abuse was located in the 
promoter region of PSEN2, a gene implicated in neurodegeneration and Alzheimer’s disease 
(O’Brien and Wong, 2011). Although we are not aware of any study directly investigating the 
link between physical abuse and these conditions in advanced age, early life factors, 
including stress and the quality of the maternal relationship, have been associated with both 
neuropsychological impairment and dementia (Pechtel and Pizzagalli, 2011, Vaillant et al., 
2014). It will therefore be of interest to test whether PSEN2 methylation mediates the effect 
of abuse on cognitive function and neurodegenerative risk. Maltreatment-associated DNAm 
changes were additionally identified in a number of other genes implicated in cognitive 
deficit and intellectual disability, including HUWE1, WBSCR17 and SMC1A (Deardorff et 
al., 2007, Nakamura et al., 2005, Vandewalle et al., 2013). 
Findings also suggest a role of other loci previously implicated in psychopathology. 
Notably, one of the most hypermethylated markers across maltreatment types was located in 
CACNA2D4. Genetic variation within this gene has been identified as a shared risk locus for 
multiple psychiatric conditions that are associated with experience of childhood adversity, 
including attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, 
and schizophrenia (Smollen et al., 2013). Interestingly, expression levels of this gene have 
been found to modulate neural hippocampal activity during emotional processing as well as 
prefrontal activity during executive tasks (Bigos et al., 2010) – functional patterns that are 
disrupted in maltreated individuals (Hart and Rubia, 2012). Furthermore, genetic variation in 
SYNJ2, another gene identified in our epigenome-wide analyses, has been linked to corpus 
callosum abnormalities (Edwards et al., 2014), which are robustly associated with 
maltreatment (McCrory et al., 2012). Other psychopathology-relevant genes included 
glutamate and GABA receptors (GRIND2D, GABBR1), which play a key role in excitatory 
and inhibitory neurotransmission, respectively (Kumar et al., 2013, Yamamoto et al., 2015). 
Prospective studies will be needed to explicitly test whether the DNAm sites identified in the 
present study associate with psychopathological outcomes and, if so, whether they may 
mediate the influence of abuse and neglect on later mental health.  
 
Gene ontology analyses contribute to a better understanding of biological pathways that 
may be affected by childhood abuse and neglect. 
Gene ontology analyses were performed to explore biological pathways that may be uniquely 
affected by specific forms of maltreatment vs those ‘shared’ across maltreatment types. With 
regards to ‘maltreatment-specific’ pathways, we found that physical abuse was primarily 
associated with DNAm variation in the vicinity of genes enriched for cardiovascular 
processes, including regulation of heart rate and myocardial hypertrophy. This is consistent 
with evidence from epidemiological studies of elevated risk of heart disease among 
individuals who were physically abused as children, even after controlling for other 
childhood stressors, adult lifestyle factors and unhealthy behaviors (Fuller-Thomson et al., 
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2010, Springer et al., 2007).  Other enriched processes of interest related to wound healing, 
fear response and regulation of stress-activated protein kinase signaling.  These pathways are 
in line with growing evidence from neuroendocrine and imaging studies of an association 
between physical abuse, HPA axis dysregulation and altered threat processing at neural and 
behavioral levels (Carpenter et al., 2011, McCrory et al., 2011, Turecki and Meaney, 2014). 
In contrast, the most enriched biological process specifically linked to neglect was regulation 
of cholesterol efflux, followed by other processes including DNA damage response, 
ribosomal function and zymogen activation.  Although this finding necessitates replication, it 
is worth noting that these processes have been shown to respond to diet and nutrient 
availability (Fenech and Bonassi, 2011, Mizushima et al., 2004), which may be particularly 
compromised in youth who have experienced neglect (as evidenced in our sample). Together, 
our data suggest that physical abuse and neglect may affect epigenetic regulation of separate 
biological pathways, which may in part underlie differential effects observed at a phenotypic 
level (Sheridan and McLaughlin, 2014). Sexual abuse could not be examined due to the 
limited number of genes showing ‘unique’ epigenetic variation, which may reflect lack of 
power due to lower prevalence rates in our sample.  
In addition to showing specific epigenetic variation, maltreatment types were also 
found to share a common methylomic signature, primarily enriched for processes related to 
neurodevelopment and organismal growth. This is consistent with a large body of evidence 
from animal and human studies documenting the impact of maltreatment and early life stress 
on brain structure, function and development. For example, maltreatment has been 
consistently associated with reduced volume of the corpus callosum, prefrontal cortex and 
hippocampus (Hart and Rubia, 2012, McCrory et al., 2012). Broader developmental delay 
and growth failure is also well established amongst maltreated children (Leslie et al., 2005, 
Olivan, 2003). Findings are also in line with previous epigenetic studies that have 
documented an association between global maltreatment exposure and DNAm changes in 
genes enriched for neural (e.g. Labonte et al, 2012: ‘neuron projection’, ‘dendrite’; Yang et 
al, 2013: ‘neurogenesis’, ‘axonal guidance’) and developmental (e.g. Suderman et al, 2014: 
‘multicellular organismal development’) processes.  In future, it will be important to explore 
whether epigenetic regulation of these ‘core’ processes in response to maltreatment is 
functionally relevant at a transcriptomic level, and whether they relate directly to other 
biological markers of neurodevelopment and growth, such as imaging data and markers of 
cellular ageing.  
Limitations and future directions 
The current findings should be interpreted in light of a number of important limitations. First, 
although rates of maltreatment in our sample were high, analyses were based on a modestly 
sized group of inner-city youth, which precluded the possibility of addressing more nuanced 
research questions (e.g. sex differences). Furthermore, our assessment of maltreatment was 
based on self-reports that lacked information regarding maltreatment timing and duration, 
both of which are likely to moderate the association between maltreatment and DNA 
methylation. In future, it will be important to replicate findings using larger samples, ideally 
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featuring externally-validated maltreatment histories that will make it possible to investigate 
how DNAm patterns may vary by age of onset and chronicity of exposure to different forms 
of maltreatment. Second, due to the high rates of polyvictimization in our sample, it was not 
feasible to compare methylomic patterns between individuals who experienced single forms 
of maltreatment in isolation. Instead, we examined methylome-wide associations for each 
maltreatment type dimensionally, and then explored the presence of unique vs shared 
signatures at a functional pathway level, as opposed to a DNAm site level. Even though 
associations were always strongest for the maltreatment type under investigation, it is 
therefore still possible that the identified sites may have in part reflected the combined effect 
of exposure to multiple maltreatment types. Furthermore, the identification of unique vs 
shared biological pathways linked to maltreatment were based on gene ontology analyses, 
which can be susceptible to bias (Timmons et al., 2015), and consequently will necessitate 
replication. Third, data on smoking status and medication use were not available in the 
present study.  As these exposures have been shown to alter DNAm patterns (particularly in 
blood; Gao et al., 2015), it will be important to replicate findings controlling for these 
potential confounders. It is noteworthy, however, that none of the DNAm sites identified in 
the present study overlapped with those found to be robustly affected by smoking in a recent 
systematic review (i.e. DNAm sites associated with smoking in at least three independent 
reports; Gao et al., 2015). Fourth, findings were based on DNAm from buccal cell samples 
and can thus only be considered to represent biomarkers of exposure. Although buccal 
epithelial cells have been shown to converge more strongly with brain methylation patterns 
compared to other peripheral tissues (e.g. blood; Smith et al., 2015), further investigation will 
be needed to establish the relevance of our findings to the brain.  Because we did not have 
access to RNA samples in the present study, we were also unable to establish the extent to 
which the identified DNAm sites associate with gene expression levels. As such, the analysis 
of transcriptomic data will be important for assessing the functional significance of the 
observed DNAm changes. Finally, the cross-sectional nature of the study meant that we were 
unable to establish the causal role of the identified DMPs. Longitudinal assessments featuring 
repeated DNAm measures will be needed to explore prospective interrelations between 
maltreatment exposure, DNAm and developmental outcomes.  
Conclusions 
The current findings shed new light on how maltreatment may alter epigenetic mechanisms 
that regulate gene expression, providing a possible biological link between early adversity 
and poor health outcomes. Different forms of maltreatment were found to have distinct as 
well as shared signatures, pointing to a complex relationship between the nature of early 
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Figure 1. Associations between DNA methylation and maltreatment types.  
(A) Manhattan plots for physical abuse, sexual abuse and physical neglect; (B) scatterplots of 
DMPs indicated in (A) for each maltreatment type; and (C) scatterplots of hyper- and hypo-
methylated DMPs across maltreatment types. N.b. The dotted line represents FDR correction 
(i.e. DMPs above the line are significant at q<0.05). 
 
Figure 2. Unique vs shared enriched biological processes across maltreatment types. 
Significantly enriched biological processes for genes uniquely associated with each 
maltreatment type (physical abuse [green], physical neglect [blue]) vs those shared across 
maltreatment types (red), based on GO analysis. GO analysis was not run independently for 
sexual abuse (SA) due to limited gene n. Circles represent GO terms that survive FDR 
correction. The X axis represents -log(10) p values. The opacity of the circles indicates level 
of significance (darker = more significant). The size of the circles indicates the percentage of 
genes in our results for a given pathway compared to the total number of genes in the same 
pathway (i.e. larger size = larger %; range = 6.51% - 100%). Abbreviations: PA, physical 
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Table 1. Descriptives and correlations between study variables. 
 
                    Ethnicityb 
Maltreatment type M (SD) 
% above threshold 
(n) 
1 2 3 4 Sex Age White Black Mixed Asian 
1. Emotional abuse 10.06 (4.99) 50.8 (63) –        .01 .17 -.13 .19* -.07 .00 
2. Physical abuse 7.82 (4.70) 33.1 (41) .57*** –      .01 .09 -.16 .26** -.08 -.06 
3. Sexual abuse 6.14 (3.51) 17.0 (21) .41*** .25*** –    .05 .13 -.11 .12 -.01 -.04 
4. Emotional neglect 10.47 (4.81) 49.2 (61) .73*** .55*** .35*** –  -.03 .18* -.20* .21* -.09 .12 
5. Physical neglect 7.55 (3.61) 32.3 (40) .65*** .60*** .36*** .71*** -.07 .14 -.22* .31*** -.11 .00 
 
 
N.B. Intercorrelations between maltreatment types, and their association with socio-demographic characteristics (age, sex and ethnicity). A 
product-moment correlation is used for associations between two continuous variables, while a point-biserial correlation is used for associations 
between one continuous and one dichotomous variable (i.e. sex, ethnicity). Bivariate correlations significant at: *p <.05, **p < .01, ***p < .001. 
a For descriptive purposes, this column shows the percentage of participants who scored above the ‘Low’ maltreatment threshold specified by the 
CTQ manual.  
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Table 2. Top 10 DMPs associated with physical abuse, sexual abuse and physical neglect. 
CpG probe Gene Chr Genomic location Position B diff.a Std .Bb P-value FDR (q) 
A. Physical abuse (N FDR-corrected DMPs = 34)           
cg20000641 PSEN2 1 TSS1500 227058046 0.14 0.55 2.53E-11 1.47E-05 
cg02353937 SMC1A/RIBC1 X TSS1500 53449152 0.09 0.50 2.90E-09 7.89E-04 
cg15440363 GPD1L 3 TSS200 32148023 0.05 0.48 2.06E-08 3.64E-03 
cg04412054 GALNS 16 Body 88897539 -0.12 -0.46 5.69E-08 0.01 
cg22311608 SMC1A/RIBC1 X TSS200 53449829 0.09 0.46 8.45E-08 0.01 
cg24365098 C11orf84 11 3'UTR 63594804 -0.12 -0.45 1.43E-07 0.01 
cg03561071 [FAT3] 11 -- 91844355 -0.11 -0.44 4.28E-07 0.03 
cg26454299 PPP3CA 4 -- 102268957 0.10 0.43 5.58E-07 0.03 
cg25047485 [ARHGAP39] 8 -- 145848944 -0.11 -0.43 8.14E-07 0.04 
cg04524770 LMF1 16 Body 946408 -0.11 -0.42 9.96E-07 0.04 
B. Sexual abuse (N FDR-corrected DMPs = 7)           
cg17106653 GRIN2D 19 TSS1500 48897279 0.22 0.50 4.16E-09 1.72E-03 
cg00974464 PRDM15 21 Body 43254115 -0.12 -0.46 6.02E-08 0.01 
cg26528551 MGMT 10 Body 131445415 -0.09 -0.46 6.84E-08 0.01 
cg10795666 MLNR 13 1stExon 49794635 0.09 0.45 2.23E-07 0.02 
cg02618355 MYOM2 8 Body 2024368 -0.09 -0.44 2.88E-07 0.02 
cg26513050 DIAPH2/RPA4 X Body 96138983 -0.18 -0.44 2.91E-07 0.02 
cg23983710 DIP2C 10 Body 370756 -0.16 -0.43 5.83E-07 0.03 
                  
C. Physical neglect (N FDR-corrected DMPs = 118)           
cg00691266 EVPL 17 Body 74015089 -0.08 -0.46 1.01E-07 0.01 
cg27083825 SYNJ2 6 Body 158453594 -0.07 -0.45 1.02E-07 0.01 
cg17918089 SETDB1 1 Body 150899251 0.08 0.45 1.14E-07 0.01 
cg10094509 MAP2K4P1/CHIC1 X TSS1500 72783579 0.09 0.45 1.16E-07 0.01 
cg09863040 JADE1 4 TSS200 129730729 0.02 0.44 2.10E-07 0.01 
cg08796898 HUWE1 X 5'UTR 53713664 0.14 0.44 3.59E-07 0.02 
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cg20668974 ZNF827 4 Body 146857981 0.06 0.44 3.63E-07 0.02 
cg18116160 GABBR1 6 Body 29575145 -0.04 -0.44 4.01E-07 0.02 
cg09084892 FAT1 4 Body 187557837 -0.12 -0.43 4.35E-07 0.02 
cg08054907 HIST1H1A 6 TSS1500 26019358 -0.09 -0.43 5.12E-07 0.02 
 
N.B. Gene names in brackets indicate the most proximal genes to the CpG probe based on Genome Studio. Genes with multiple significant 
probes are highlighted in blue.  
a Beta differences indicate the overall difference (% methylation change) between the predicted unstandardized minimum and maximum values 
of the linear model. 
b Standardized Beta estimates are used as a measure of effect size, where an effect of 0.10 is small effect, an effect of 0.24 is a medium effect, 
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Table 3. Top 20 hyper- and hypo-methylated DMPs across maltreatment types (physical abuse, sexual abuse and neglect), ranked by average 
effect size.  
  CpG probe Gene Chr Genomic 
location 
Position Physical Abuse   Sexual Abuse    Neglect   Average 
StdB           StdB                     p-value                       StdB                       p-value                    StdB                       p-value                      
A. Hypermethylated                           
  cg08796898 HUWE1 X 5'UTR 53713664 0.38 1.10E-05   0.21 2.19E-02   0.44 3.83E-07   0.34 
  cg21239691 GEMIN8 X TSS200 14048191 0.42 1.24E-06   0.18 4.38E-02   0.39 7.20E-06   0.33 
  cg04704856 FMOD 1 1stExon 203320190 0.32 2.46E-04   0.27 2.61E-03   0.37 2.36E-05   0.32 
  cg12986338 [PDE1C] 7 -- 32338950 0.28 1.39E-03   0.31 4.15E-04   0.35 6.27E-05   0.32 
  cg23436576 TDH 8 Body 11204132 0.35 7.16E-05   0.23 8.75E-03   0.35 6.17E-05   0.31 
  cg25051341 PRDM13 6 Body 100061307 0.27 2.79E-03   0.28 1.40E-03   0.38 1.30E-05   0.31 
  cg19637330 [PAX7] 1 -- 19110922 0.26 3.73E-03   0.31 4.51E-04   0.36 3.98E-05   0.31 
  cg26163537 GRB10 7 TSS1500 50861592 0.36 3.84E-05   0.19 3.76E-02   0.38 1.37E-05   0.31 
  cg25579180 WBSCR17 7 Body 71098623 0.36 4.53E-05   0.32 3.03E-04   0.25 5.24E-03   0.31 
  cg12627354 LRP4 11 TSS1500 46940434 0.26 3.29E-03   0.28 1.56E-03   0.38 1.67E-05   0.31 
  cg08121755 [KRT80] 12 -- 52545978 0.27 2.15E-03   0.34 1.39E-04   0.29 9.09E-04   0.30 
  cg03309770 TVP23A 16 1stExon 10912478 0.38 1.17E-05   0.21 1.66E-02   0.30 6.53E-04   0.30 
  cg21453209 [ZFAND1] 8 -- 82635831 0.32 3.47E-04   0.25 5.99E-03   0.33 2.23E-04   0.30 
  cg20594607 LOC338799 12 TSS200 122241438 0.33 1.94E-04   0.24 7.13E-03   0.31 3.81E-04   0.29 
  cg26840590 PHF1 6 5'UTR 33379330 0.32 2.86E-04   0.22 1.23E-02   0.34 1.39E-04   0.29 
  cg04530860 B9D2 19 TSS200 41870213 0.38 1.69E-05   0.24 7.20E-03   0.26 3.45E-03   0.29 
  cg17962547 GPR123 10 Body 134918974 0.32 3.57E-04   0.25 5.39E-03   0.31 4.39E-04   0.29 
  cg11480019 ADK 10 -- 75936982 0.30 8.66E-04   0.32 3.13E-04   0.25 4.48E-03   0.29 
  cg09387749 HOXD3 2 TSS200 177028680 0.31 5.34E-04   0.24 7.14E-03   0.32 3.50E-04   0.29 
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B. Hypomethylated                           
  cg10494397 CC2D2A 4 Body 15593854 -0.39 7.89E-06   -0.24 6.61E-03   -0.42 1.35E-06   -0.35 
  cg27496299 DNAJB6 7 Body 157171202 -0.38 1.56E-05   -0.28 1.84E-03   -0.39 6.90E-06   -0.35 
  cg27632471 C20orf96 20 Body 259123 -0.27 2.41E-03   -0.39 8.78E-06   -0.39 9.42E-06   -0.35 
  cg07870603 RPTOR 17 Body 78880144 -0.28 1.37E-03   -0.38 1.43E-05   -0.33 2.28E-04   -0.33 
  cg09596252 RPTOR 17 Body 78655493 -0.41 3.00E-06   -0.28 1.62E-03   -0.30 7.06E-04   -0.33 
  cg01786585 TIAM2 6 -- 155315188 -0.37 2.00E-05   -0.35 8.70E-05   -0.26 3.59E-03   -0.33 
  cg23523534 NLRP11 19 5'UTR 56347927 -0.33 1.45E-04   -0.32 3.12E-04   -0.32 3.59E-04   -0.32 
  cg16560389 [TCERG1L] 10 -- 133318201 -0.34 9.50E-05   -0.22 1.32E-02   -0.40 3.60E-06   -0.32 
  cg05157878 GCNT2 6 -- 10494860 -0.29 1.05E-03   -0.38 1.57E-05   -0.29 1.30E-03   -0.32 
  cg21473728 MYOM2 8 Body 2031651 -0.36 4.62E-05   -0.20 2.57E-02   -0.39 7.42E-06   -0.32 
  cg21385432 EP400 12 Body 132512858 -0.31 4.33E-04   -0.24 6.55E-03   -0.39 7.04E-06   -0.32 
  cg19279265 ACOX3 4 Body 8388670 -0.27 2.83E-03   -0.41 1.73E-06   -0.26 3.66E-03   -0.31 
  cg03561071 [FAT3] 11 -- 91844355 -0.44 4.28E-07   -0.22 1.35E-02   -0.28 1.99E-03   -0.31 
  cg22896075 GJD3 17 1stExon 38518413 -0.40 5.30E-06   -0.21 2.04E-02   -0.32 3.09E-04   -0.31 
  cg13521944 C22orf9 22 Body 45596948 -0.27 2.45E-03   -0.28 1.69E-03   -0.37 2.97E-05   -0.30 
  cg11650926 [KIAA0947] 5 -- 5568539 -0.30 8.71E-04   -0.19 3.40E-02   -0.43 6.91E-07   -0.30 
  cg21076890 COL4A2 13 Body 110965662 -0.30 8.61E-04   -0.19 3.93E-02   -0.43 5.51E-07   -0.30 
  cg03500617 [FA2H] 16 -- 74812570 -0.31 4.27E-04   -0.19 3.11E-02   -0.41 2.86E-06   -0.30 
  cg02866700 CARS2 13 Body 111333333 -0.30 7.85E-04   -0.26 3.98E-03   -0.35 5.79E-05   -0.30 
  cg13920529 SUGT1P1 9 Body 33402426 -0.34 9.08E-05   -0.21 1.85E-02   -0.35 6.28E-05   -0.30 
 
 
N.B. Gene names in brackets indicate the most proximal genes to the CpG probe based on Genome Studio. Genes with multiple significant 
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OS1. Optimized gene ontology (GO) method 
A logistic regression approach was used to test if genes in the test list predicted pathway membership while 
controlling for the number probes annotated to each gene. Pathways were downloaded from the Gene Ontology 
website and all genes annotated to parent terms were also included. Illumina UCSC gene annotation was used to 
create a test gene list from probes that shown unique vs shared associations with maltreatment, depending on the 
analysis performed. All genes with at least one methylation probe annotated and annotated to at least one GO 
pathway were considered. Pathways were filtered to those with between 10 and 2000 genes in. After applying this 
method to all pathways, significant pathways (p < 0.05) were taken and grouped where overlapping genes 
explained the signal. This was achieved by taking the most significant pathway, and retesting all remaining 
significant pathways while controlling additionally for the best term. If genes in the test list no longer predicted 
the pathway, the term was said to be explained by the most significant pathway, and hence these pathways were 
grouped together. This algorithm was repeated, taking the next most significant term, until all pathways had been 
considered as the most significant or found to be explained by a more significant term. GO terms were interpreted 
exclusively if they if they contained more than 1 gene and passed FDR-correction, based on the final list of 













OS2. Top 10 DMPs associated with emotional abuse and emotional neglect 
CpG probe Gene Chr Genomic location Position Std .B P-value 
FDR 
(q) 
A. Emotional abuse             
cg23436576 TDH 8 Body 11204132 0.38 1.17E-05 1.00 
cg10933494 [ZNF311] 6 -- 28983143 -0.38 1.56E-05 1.00 
cg00742603 DBNDD1 16 TSS1500 90086301 0.37 1.89E-05 1.00 
cg00347856 [FLJ45974] 7 -- 53879253 -0.37 1.95E-05 1.00 
cg18116160 GABBR1 6 Body 29575145 -0.37 2.48E-05 1.00 
cg11496014 [BUB3] 10 -- 125115762 -0.36 3.43E-05 1.00 
cg00436603 CYP2E1 10 TSS200 135340740 0.36 3.87E-05 1.00 
cg13778848 LOC283050 10 Body 80746999 -0.35 6.40E-05 1.00 
cg04477202 SPAST 2 Body 32289458 0.35 7.76E-05 1.00 
cg01067603 DAB1 1 5'UTR 58331989 -0.35 7.78E-05 1.00 
B. Emotional neglect             
cg21964928 [SAP30L] 5 -- 153872958 0.38 1.62E-05 1.00 
cg19050351 IL1F5 2 Body 113820090 -0.37 2.48E-05 1.00 
cg01630869 CDC42EP2 11 -- 65082120 0.36 3.18E-05 1.00 
cg10933494 [ZNF311] 6 -- 28983143 -0.36 3.31E-05 1.00 
cg07603484 NUP62 19 TSS1500 50434179 -0.35 5.99E-05 1.00 
cg18994566 ZFYVE21 14 Body 104191347 -0.35 6.71E-05 1.00 
cg13161621 IQSEC2 X Body 53348705 0.35 6.81E-05 1.00 
cg13688202 SPTB 14 Body 65230287 -0.35 8.06E-05 1.00 
cg09796576 ZNF526 19 Body 42729528 -0.35 8.28E-05 1.00 
cg18852899 RMDN2 2 -- 38154797 -0.35 8.33E-05 1.00 
 
N.B. Gene names in brackets indicate the most proximal genes to the CpG probe based on Genome Studio. Standardized 
Beta estimates are used as a measure of effect size, where an effect of 0.10 is small effect, an effect of 0.24 is a medium 













OS3. Full list of FDR-corrected DMPs associated with physical abuse, sexual abuse and physical neglect 
CpG probe Gene Chr 
Genomic 
location 
Position Std .B P-value FDR (q) 
A. Physical abuse (FDRn = 34)             
cg20000641 PSEN2 1 TSS1500 227058046 0.55 2.53E-11 1.47E-05 
cg02353937 SMC1A/RIBC1 X TSS1500 53449152 0.50 2.90E-09 7.89E-04 
cg15440363 GPD1L 3 TSS200 32148023 0.48 2.06E-08 3.64E-03 
cg04412054 GALNS 16 Body 88897539 -0.46 5.69E-08 0.01 
cg22311608 SMC1A/RIBC1 X TSS200 53449829 0.46 8.45E-08 0.01 
cg24365098 C11orf84 11 3'UTR 63594804 -0.45 1.43E-07 0.01 
cg03561071 -- 11 -- 91844355 -0.44 4.28E-07 0.03 
cg26454299 PPP3CA 4 -- 102268957 0.43 5.58E-07 0.03 
cg25047485 -- 8 -- 145848944 -0.43 8.14E-07 0.04 
cg04524770 LMF1 16 Body 946408 -0.42 9.96E-07 0.04 
cg16856833 -- 3 -- 87138640 0.42 1.01E-06 0.04 
cg19736040 SHC2 19 Body 451261 -0.42 1.14E-06 0.04 
cg21239691 GEMIN8 X TSS200 14048191 0.42 1.24E-06 0.04 
cg10390589 SAE1 19 TSS200 47634047 0.42 1.37E-06 0.04 
cg04554728 -- 1 -- 150185568 -0.42 1.50E-06 0.04 
cg16193029 FBXW12 3 TSS200 48413550 -0.42 1.60E-06 0.04 
cg02350090 -- 5 -- 1951736 -0.41 1.70E-06 0.04 
cg03013329 IMPACT 18 Body 22006989 0.41 1.74E-06 0.04 
cg08879390 -- 19 -- 13979907 -0.41 1.80E-06 0.04 
cg03402073 PMM1 22 Body 41974480 -0.41 1.95E-06 0.04 
cg26151355 KLHL6 3 Body 183226025 -0.41 2.01E-06 0.04 
cg10370025 ABR 17 -- 926264 -0.41 2.12E-06 0.04 
cg12710220 PRKAG2 7 Body 151423672 -0.41 2.23E-06 0.04 
cg07486666 -- 7 -- 41170679 -0.41 2.47E-06 0.04 
cg26005482 -- 6 -- 449134 -0.41 2.48E-06 0.04 
cg19115205 LOC340094 5 -- 5062128 -0.41 2.56E-06 0.04 
cg16210526 TTC40 10 -- 134663864 -0.41 2.81E-06 0.04 
cg09596252 RPTOR 17 Body 78655493 -0.41 3.00E-06 0.04 
cg20560091 ITGA11 15 Body 68624879 -0.40 3.16E-06 0.04 
cg05795849 ITPR1 3 Body 4794082 0.40 3.37E-06 0.04 
cg24399376 LOC100133545 11 Body 2005497 -0.40 3.47E-06 0.04 
cg10471356 ATP11A 13 Body 113382760 -0.40 3.59E-06 0.04 
cg23261530 RPS6KA2 6 Body 167017999 -0.40 3.61E-06 0.04 
cg20770311 SMPD1 11 TSS1500 6411396 0.40 3.64E-06 0.04 
                
B. Sexual abuse (FDRn = 7)             
cg17106653 GRIN2D 19 TSS1500 48897279 0.50 4.16E-09 1.72E-03 
cg00974464 PRDM15 21 Body 43254115 -0.46 6.02E-08 0.01 
cg26528551 MGMT 10 Body 131445415 -0.46 6.84E-08 0.01 
cg10795666 MLNR 13 1stExon 49794635 0.45 2.23E-07 0.02 
cg02618355 MYOM2 8 Body 2024368 -0.44 2.88E-07 0.02 
cg26513050 DIAPH2/RPA4 X Body 96138983 -0.44 2.91E-07 0.02 
cg23983710 DIP2C 10 Body 370756 -0.43 5.83E-07 0.03 





C. Physical neglect (FDRn = 118)             
cg00691266 EVPL 17 Body 74015089 -0.46 1.01E-07 0.01 
cg27083825 SYNJ2 6 Body 158453594 -0.45 1.02E-07 0.01 
cg17918089 SETDB1 1 Body 150899251 0.45 1.14E-07 0.01 
cg10094509 MAP2K4P1/CHIC1 X TSS1500 72783579 0.45 1.16E-07 0.01 
cg09863040 JADE1 4 TSS200 129730729 0.44 2.10E-07 0.01 
cg08796898 HUWE1 X 5'UTR 53713664 0.44 3.59E-07 0.02 
cg20668974 ZNF827 4 Body 146857981 0.44 3.63E-07 0.02 
cg18116160 GABBR1 6 Body 29575145 -0.44 4.01E-07 0.02 
cg09084892 FAT1 4 Body 187557837 -0.43 4.35E-07 0.02 
cg08054907 HIST1H1A 6 TSS1500 26019358 -0.43 5.12E-07 0.02 
cg21076890 COL4A2 13 Body 110965662 -0.43 5.18E-07 0.02 
cg17742334 -- 1 -- 9489130 0.43 5.31E-07 0.02 
cg11650926 -- 5 -- 5568539 -0.43 6.50E-07 0.02 
cg13409248 ENTPD3 3 TSS200 40428643 0.43 7.50E-07 0.02 
cg09155575 ORMDL3 17 TSS200 38084037 0.43 8.07E-07 0.02 
cg07728092 EIF5A2 3 TSS1500 170626980 -0.42 8.55E-07 0.02 
cg18458353 CEACAM5 19 TSS1500 42211171 0.42 8.89E-07 0.02 
cg21845580 SPRYD3 12 Body 53472882 0.42 9.37E-07 0.02 
cg21634218 FLJ26850 19 TSS1500 50553699 0.42 1.01E-06 0.02 
cg17693420 ZNF655 7 5'UTR 99157059 0.42 1.06E-06 0.02 
cg04480325 -- 2 -- 37422917 -0.42 1.09E-06 0.02 
cg06779606 CARD11 7 5'UTR 3041079 -0.42 1.14E-06 0.02 
cg10494397 CC2D2A 4 Body 15593854 -0.42 1.28E-06 0.02 
cg00311772 PPP1R7 2 Body 242092919 -0.42 1.32E-06 0.02 
cg26248645 PELI1 2 5'UTR 64370690 0.42 1.36E-06 0.02 
cg18001780 -- 11 -- 128500564 0.42 1.48E-06 0.02 
cg18022926 PBLD/HNRNPH3 10 TSS1500 70093071 0.42 1.54E-06 0.02 
cg02550027 BLOC1S2 10 TSS1500 102046474 0.41 1.64E-06 0.02 
cg17309464 ZNF565 19 5'UTR 36705192 0.41 1.96E-06 0.02 
cg04586332 -- 22 -- 45659810 0.41 2.00E-06 0.02 
cg07032930 MRPL53 2 3'UTR 74699212 0.41 2.16E-06 0.03 
cg02430183 WNK2 9 1stExon 95947766 -0.41 2.17E-06 0.03 
cg06850509 -- 2 -- 96314847 -0.41 2.22E-06 0.03 
cg24114390 FAM133A X TSS1500 92928730 0.41 2.32E-06 0.03 
cg17822007 -- 3 -- 155463780 0.41 2.37E-06 0.03 
cg14030997 -- 9 -- 108420639 -0.41 2.49E-06 0.03 
cg14679558 -- 13 -- 21652153 -0.41 2.70E-06 0.03 
cg12637205 CYLD 16 5'UTR 50776628 0.41 2.71E-06 0.03 
cg09090582 CNPY1 7 5'UTR 155324691 0.41 2.77E-06 0.03 
cg03500617 -- 16 -- 74812570 -0.41 2.86E-06 0.03 
cg10493855 TTC7B 14 Body 91087586 -0.41 2.89E-06 0.03 
cg14945917 -- 4 -- 38145641 -0.41 2.95E-06 0.03 
cg16539640 CYFIP1 15 Body 22945028 -0.41 2.98E-06 0.03 
cg02564272 MAN1A1 6 Body 119507963 -0.41 3.04E-06 0.03 
cg18073471 PRDM8 4 5'UTR 81119198 0.40 3.24E-06 0.03 
cg27568885 GCNT3 15 Body 59911449 -0.40 3.45E-06 0.03 
cg13468418 -- 4 -- 186048907 0.40 3.54E-06 0.03 
cg16560389 -- 10 -- 133318201 -0.40 3.60E-06 0.03 
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cg16210526 -- 10 -- 134663864 -0.40 3.71E-06 0.03 
cg13521097 FERMT2 14 5'UTR 53417433 0.40 3.85E-06 0.03 
cg15799267 ALOX15B 17 5'UTR 7942406 0.40 4.08E-06 0.03 
cg19270277 CROCC 1 Body 17296995 -0.40 4.10E-06 0.03 
cg04375213 DCP1B 12 Body 2113435 0.40 4.12E-06 0.03 
cg13109184 LYST 1 -- 236029439 0.40 4.40E-06 0.03 
cg22902505 PRDM8 4 5'UTR 81119473 0.40 4.79E-06 0.04 
cg08614562 KIF1A 2 Body 241665572 -0.40 5.13E-06 0.04 
cg19864758 PCSK2 20 TSS1500 17206720 0.40 5.19E-06 0.04 
cg27063720 EP400NL 12 Body 132568987 0.40 5.23E-06 0.04 
cg24604043 SLC39A3 19 TSS1500 2740392 0.40 5.34E-06 0.04 
cg15136913 -- 10 -- 134893540 -0.40 5.38E-06 0.04 
cg19091677 HMGB2 4 TSS1500 174255518 0.40 5.44E-06 0.04 
cg10625723 -- 4 -- 6235503 -0.40 5.50E-06 0.04 
cg07821496 TDRKH 1 5'UTR 151762942 0.40 5.51E-06 0.04 
cg08294772 -- 8 -- 138135392 0.40 5.52E-06 0.04 
cg26309691 SCCPDH 1 Body 246887944 0.39 6.14E-06 0.04 
cg21074877 -- 14 -- 23481968 -0.39 6.54E-06 0.04 
cg19827167 MIR760 1 TSS200 94312206 0.39 6.56E-06 0.04 
cg27330720 FBXL20 17 TSS1500 37558981 0.39 6.67E-06 0.04 
cg05130304 C3orf23 3 TSS1500 44379503 0.39 6.72E-06 0.04 
cg26509269 -- 17 -- 34970306 -0.39 6.89E-06 0.04 
cg27496299 DNAJB6 7 Body 157171202 -0.39 6.90E-06 0.04 
cg02458885 PRDM8 4 5'UTR 81119249 0.39 6.93E-06 0.04 
cg21385432 EP400 12 Body 132512858 -0.39 7.04E-06 0.04 
cg06874656 NTM 11 TSS1500 131780353 0.39 7.10E-06 0.04 
cg21239691 GEMIN8 X TSS200 14048191 0.39 7.20E-06 0.04 
cg00895834 PRDM16 1 Body 3147966 -0.39 7.20E-06 0.04 
cg21473728 MYOM2 8 Body 2031651 -0.39 7.42E-06 0.04 
cg10390589 SAE1 19 TSS200 47634047 0.39 7.64E-06 0.04 
cg10246772 IGF1R 15 Body 99250916 -0.39 7.90E-06 0.04 
cg02514021 FLJ43663 7 Body 130791171 0.39 8.24E-06 0.04 
cg10609984 ZNF25 10 TSS200 38265593 0.39 8.43E-06 0.04 
cg25087154 IL1RAP 3 TSS1500 190231338 0.39 8.47E-06 0.04 
ch.11.150171F NUP98 11 Body 3739920 0.39 9.00E-06 0.04 
cg23284284 GIGYF2 2 TSS200 233561917 0.39 9.02E-06 0.04 
cg01093285 PTPRN2 7 Body 157436506 -0.39 9.38E-06 0.04 
cg27632471 C20orf96 20 Body 259123 -0.39 9.42E-06 0.04 
cg12411309 SMUG1 12 5'UTR 54582659 0.39 9.51E-06 0.04 
cg17341361 TNRC18 7 Body 5414170 -0.39 9.51E-06 0.04 
cg07124687 -- 6 -- 28956332 0.39 9.71E-06 0.04 
cg12154976 RASGEF1C 5 5'UTR 179585198 -0.39 9.84E-06 0.04 
cg12398448 IGF1R 15 Body 99251461 -0.39 9.87E-06 0.04 
cg10462751 RIC8B 12 TSS200 107168330 0.38 1.03E-05 0.05 
cg04204072 THUMPD1 16 1stExon 20752857 0.38 1.04E-05 0.05 
cg10962490 GLIS1 1 5'UTR 54072456 -0.38 1.05E-05 0.05 
cg13653274 -- 10 -- 132632928 -0.38 1.07E-05 0.05 
cg15472403 OSCAR 19 Body 54599455 0.38 1.09E-05 0.05 
cg00014152 WDR13 X Body 48457128 -0.38 1.10E-05 0.05 
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cg25247351 HLA-DMB 6 1stExon 32908794 0.38 1.11E-05 0.05 
cg03156396 MSLN 16 Body 816177 -0.38 1.13E-05 0.05 
cg10650870 TNPO1 5 Body 72144764 0.38 1.15E-05 0.05 
cg01487433 CILP2 19 TSS200 19648987 -0.38 1.15E-05 0.05 
cg22533689 EPHA2 1 Body 16464479 -0.38 1.16E-05 0.05 
cg13735965 ZNF616 19 TSS1500 52643487 0.38 1.18E-05 0.05 
cg07307426 DET1 15 5'UTR 89089587 0.38 1.18E-05 0.05 
cg25002318 TRPV1 17 Body 3471868 -0.38 1.20E-05 0.05 
cg19554389 WNT5A 3 1stExon 55521134 0.38 1.20E-05 0.05 
cg16953816 VPS37B 12 3'UTR 123349952 -0.38 1.22E-05 0.05 
cg14604000 C5orf13 5 TSS1500 111093875 0.38 1.24E-05 0.05 
cg11969467 MRPS14 1 TSS200 174992598 0.38 1.24E-05 0.05 
cg03998119 PTPN21 14 Body 88945315 -0.38 1.25E-05 0.05 
cg03041046 SPRYD3 12 5'UTR 53473136 0.38 1.27E-05 0.05 
cg25051341 PRDM13 6 Body 100061307 0.38 1.30E-05 0.05 
cg01407073 NAP1L1 12 TSS200 76478898 0.38 1.30E-05 0.05 
cg15874300 CRBN 3 Body 3221199 0.38 1.31E-05 0.05 
cg13144843 -- 3 -- 174158740 0.38 1.33E-05 0.05 
cg26163537 GRB10 7 TSS1500 50861592 0.38 1.37E-05 0.05 
cg20657691 RBM3 X TSS1500 48432562 0.38 1.38E-05 0.05 
cg06616055 MUPCDH 11 Body 623756 0.38 1.42E-05 0.05 
 
N.B. Genes with multiple significant probes are highlighted in blue. Standardized Beta estimates are used as a 
measure of effect size, where an effect of 0.10 is small effect, an effect of 0.24 is a medium effect, and an effect 























OS5: Sensitivity analyses for FDR-corrected DMPs associated with physical abuse, sexual abuse and physical neglect 
CpG probe Gene Chr 
Genomic 
location 
Position     Sensitivity Analyses   




          p-value q-value   p-value q-value   p-value q-value    B 95% CI 
A. Physical abuse (n = 34)                                 
cg20000641 PSEN2 1 TSS1500 227058046 2.53E-11 1.47E-05   4.205E-09 4.91E-04   1.64E-03 0.61   -0.006 -0.010 -0.001 * 
cg02353937 SMC1A/RIBC1 X TSS1500 53449152 2.90E-09 7.89E-04   1.922E-08 1.35E-03   1.26E-04 0.42   -0.006 -0.012 -0.001 * 
cg15440363 GPD1L 3 TSS200 32148023 2.06E-08 3.64E-03   3.819E-09 4.91E-04   0.05 0.76   -0.005 -0.009 -0.001 * 
cg04412054 GALNS 16 Body 88897539 5.69E-08 0.01   1.244E-05 0.04   0.01 0.69   -0.005 -0.010 -0.001 * 
cg22311608 SMC1A/RIBC1 X TSS200 53449829 8.45E-08 0.01   1.486E-05 0.04   1.50E-05 0.22   -0.006 -0.011 -0.001 * 
cg24365098 C11orf84 11 3'UTR 63594804 1.43E-07 0.01   8.455E-05 0.07   9.76E-03 0.69   -0.009 -0.014 -0.003 - 
cg03561071 [FAT3] 11 -- 91844355 4.28E-07 0.03   1.174E-06 0.01   7.25E-04 0.58   -0.004 -0.006 -0.001 * 
cg26454299 PPP3CA 4 -- 102268957 5.58E-07 0.03   1.073E-05 0.04   9.16E-04 0.59   -0.006 -0.010 -0.001 * 
cg25047485 [ARHGAP39] 8 -- 145848944 8.14E-07 0.04   1.857E-05 0.04   0.01 0.69   -0.004 -0.006 -0.003 * 
cg04524770 LMF1 16 Body 946408 9.96E-07 0.04   1.270E-06 0.01   0.02 0.72   -0.012 -0.020 -0.004 * 
cg16856833 [VGLL3 ] 3 -- 87138640 1.01E-06 0.04   1.605E-05 0.04   1.29E-03 0.60   -0.006 -0.011 -0.001 * 
cg19736040 SHC2 19 Body 451261 1.14E-06 0.04   8.149E-06 0.03   3.69E-03 0.64   -0.003 -0.005 -0.001 * 
cg21239691 GEMIN8 X TSS200 14048191 1.24E-06 0.04   8.405E-04 0.15   1.22E-05 0.22   -0.004 -0.006 -0.001 - 
cg10390589 SAE1 19 TSS200 47634047 1.37E-06 0.04   1.177E-06 0.01   4.86E-03 0.65   -0.003 -0.006 0.000 - 
cg04554728 [ANP32E ] 1 -- 150185568 1.50E-06 0.04   5.394E-07 0.01   1.08E-03 0.60   -0.008 -0.016 -0.002 * 
cg16193029 FBXW12 3 TSS200 48413550 1.60E-06 0.04   8.757E-06 0.04   0.48 0.90   -0.012 -0.022 -0.004 - 
cg02350090 [IRX4 ] 5 -- 1951736 1.70E-06 0.04   5.984E-05 0.06   2.04E-06 0.19   -0.006 -0.010 -0.002 - 
cg03013329 IMPACT 18 Body 22006989 1.74E-06 0.04   4.188E-04 0.13   9.24E-03 0.68   -0.003 -0.005 -0.002 - 
cg08879390 [NANOS3] 19 -- 13979907 1.80E-06 0.04   6.189E-06 0.03   1.47E-03 0.61   -0.003 -0.005 -0.001 * 
cg03402073 PMM1 22 Body 41974480 1.95E-06 0.04   2.855E-05 0.05   7.61E-03 0.67   -0.004 -0.008 -0.001 * 
cg26151355 KLHL6 3 Body 183226025 2.01E-06 0.04   1.771E-04 0.10   6.15E-03 0.67   -0.003 -0.006 -0.001 - 
cg10370025 ABR 17 -- 926264 2.12E-06 0.04   1.124E-05 0.04   3.74E-03 0.64   -0.002 -0.003 0.000 - 
cg12710220 PRKAG2 7 Body 151423672 2.23E-06 0.04   7.008E-06 0.03   7.05E-03 0.67   -0.003 -0.005 -0.002 * 
cg07486666 [C7orf10] 7 -- 41170679 2.47E-06 0.04   2.865E-05 0.05   0.02 0.73   0.002 0.000 0.003 - 
cg26005482 [IRF4] 6 -- 449134 2.48E-06 0.04   4.799E-05 0.06   2.32E-03 0.63   0.006 0.002 0.011 - 
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cg19115205 LOC340094 5 -- 5062128 2.56E-06 0.04   7.828E-06 0.03   6.99E-05 0.40   0.005 0.001 0.009 * 
cg16210526 TTC40 10 -- 134663864 2.81E-06 0.04   8.721E-07 0.01   1.01E-05 0.22   0.002 0.000 0.004 - 
cg09596252 RPTOR 17 Body 78655493 3.00E-06 0.04   6.730E-05 0.07   2.63E-04 0.47   0.005 0.002 0.008 - 
cg20560091 ITGA11 15 Body 68624879 3.16E-06 0.04   2.024E-05 0.05   2.35E-04 0.47   0.004 0.001 0.007 * 
cg05795849 ITPR1 3 Body 4794082 3.37E-06 0.04   3.684E-08 1.84E-03   3.42E-04 0.51   0.005 0.001 0.008 * 
cg24399376 LOC100133545 11 Body 2005497 3.47E-06 0.04   5.354E-05 0.06   1.38E-03 0.61   0.004 0.002 0.007 - 
cg10471356 ATP11A 13 Body 113382760 3.59E-06 0.04   4.097E-05 0.05   1.53E-03 0.61   0.003 0.000 0.005 - 
cg23261530 RPS6KA2 6 Body 167017999 3.61E-06 0.04   3.408E-05 0.05   4.74E-05 0.37   0.004 0.002 0.007 * 
cg20770311 SMPD1 11 TSS1500 6411396 3.64E-06 0.04   1.204E-06 0.01   2.48E-03 0.63   0.007 0.002 0.012 * 
                                    
B. Sexual abuse (n = 7)                                 
cg17106653 GRIN2D 19 TSS1500 48897279 4.16E-09 1.72E-03   8.46E-10 1.75E-04   0.03 1.00   0.011 -0.001 0.020 - 
cg00974464 PRDM15 21 Body 43254115 6.02E-08 0.01   3.21E-09 3.32E-04   0.15 1.00   -0.006 -0.012 0.000 - 
cg26528551 MGMT 10 Body 131445415 6.84E-08 0.01   2.66E-09 3.32E-04   0.04 1.00   -0.005 -0.010 0.000 - 
cg10795666 MLNR 13 1stExon 49794635 2.23E-07 0.02   1.21E-07 3.85E-03   1.90E-05 1.00   0.005 0.002 0.009 * 
cg02618355 MYOM2 8 Body 2024368 2.88E-07 0.02   3.58E-08 1.85E-03   0.03 1.00   -0.004 -0.011 0.000 - 
cg26513050 DIAPH2/RPA4 X Body 96138983 2.91E-07 0.02   1.00E-07 3.46E-03   0.30 1.00   -0.009 -0.024 0.001 - 
cg23983710 DIP2C 10 Body 370756 5.83E-07 0.03   2.32E-11 9.59E-06   0.05 1.00   -0.008 -0.013 0.000 - 
                                    
C. Physical neglect (n = 118)                                 
cg00691266 EVPL 17 Body 74015089 1.01E-07 0.01   3.27E-04 0.19   2.75E-05 0.13   -0.005 -0.007 -0.003 - 
cg27083825 SYNJ2 6 Body 158453594 1.02E-07 0.01   1.39E-03 0.28   2.50E-04 0.15   -0.005 -0.008 -0.002 - 
cg17918089 SETDB1 1 Body 150899251 1.14E-07 0.01   2.80E-09 1.04E-03   3.14E-03 0.19   0.005 0.001 0.009 * 
cg10094509 MAP2K4P1/CHIC1 X TSS1500 72783579 1.16E-07 0.01   3.82E-05 0.10   6.72E-06 0.12   0.006 0.001 0.011 - 
cg09863040 JADE1 4 TSS200 129730729 2.10E-07 0.01   6.01E-07 0.02   7.85E-06 0.12   0.001 0 0.001 - 
cg08796898 HUWE1 X 5'UTR 53713664 3.59E-07 0.02   2.48E-04 0.18   2.23E-05 0.13   0.01 0.005 0.014 - 
cg20668974 ZNF827 4 Body 146857981 3.63E-07 0.02   2.13E-06 0.04   4.10E-05 0.13   0.004 0.002 0.006 * 
cg18116160 GABBR1 6 Body 29575145 4.01E-07 0.02   8.27E-05 0.13   3.07E-06 0.11   -0.002 -0.004 -0.001 - 
cg09084892 FAT1 4 Body 187557837 4.35E-07 0.02   4.65E-05 0.11   0.01 0.23   -0.008 -0.013 -0.002 - 
cg08054907 HIST1H1A 6 TSS1500 26019358 5.12E-07 0.02   3.85E-05 0.10   1.13E-04 0.14   -0.006 -0.01 -0.002 - 
cg21076890 COL4A2 13 Body 110965662 5.18E-07 0.02   1.09E-03 0.26   4.96E-04 0.16   -0.006 -0.01 -0.002 - 
cg17742334 [SLC25A33] 1 -- 9489130 5.31E-07 0.02   1.56E-04 0.15   1.27E-04 0.14   0.003 0.001 0.006 - 
cg11650926 [ADAMTS16] 5 -- 5568539 6.50E-07 0.02   1.13E-03 0.26   1.71E-03 0.17   -0.003 -0.006 -0.001 - 
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cg13409248 ENTPD3 3 TSS200 40428643 7.50E-07 0.02   9.30E-05 0.13   1.34E-04 0.14   0.002 0.001 0.003 - 
cg09155575 ORMDL3 17 TSS200 38084037 8.07E-07 0.02   1.67E-07 0.02   0.09 0.35   0.005 0.001 0.01 - 
cg07728092 EIF5A2 3 TSS1500 170626980 8.55E-07 0.02   1.80E-04 0.16   6.75E-05 0.13   -0.002 -0.004 -0.001 - 
cg18458353 CEACAM5 19 TSS1500 42211171 8.89E-07 0.02   1.32E-06 0.04   1.57E-06 0.10   0.008 0.005 0.011 * 
cg21845580 SPRYD3 12 Body 53472882 9.37E-07 0.02   5.37E-06 0.05   4.57E-06 0.12   0.005 0.003 0.007 * 
cg21634218 FLJ26850 19 TSS1500 50553699 1.01E-06 0.02   4.31E-03 0.35   6.95E-04 0.16   0.011 0.005 0.018 - 
cg17693420 ZNF655 7 5'UTR 99157059 1.06E-06 0.02   6.95E-04 0.23   3.69E-03 0.19   0.006 0.002 0.009 - 
cg04480325 [SULT6B1] 2 -- 37422917 1.09E-06 0.02   6.15E-03 0.38   8.24E-05 0.13   -0.006 -0.012 -0.003 - 
cg06779606 CARD11 7 5'UTR 3041079 1.14E-06 0.02   1.59E-04 0.15   4.03E-05 0.13   -0.006 -0.008 -0.003 - 
cg10494397 CC2D2A 4 Body 15593854 1.28E-06 0.02   5.73E-03 0.37   1.70E-03 0.17   -0.002 -0.005 -0.001 - 
cg00311772 PPP1R7 2 Body 242092919 1.32E-06 0.02   9.47E-06 0.07   7.11E-06 0.12   -0.006 -0.009 -0.003 - 
cg26248645 PELI1 2 5'UTR 64370690 1.36E-06 0.02   3.21E-06 0.05   5.00E-04 0.16   0.006 0.001 0.012 * 
cg18001780 [ETS1] 11 -- 128500564 1.48E-06 0.02   3.98E-05 0.11   2.41E-04 0.15   0.005 0.002 0.007 - 
cg18022926 PBLD/HNRNPH3 10 TSS1500 70093071 1.54E-06 0.02   5.38E-06 0.05   0.05 0.31   0.005 0.001 0.011 * 
cg02550027 BLOC1S2 10 TSS1500 102046474 1.64E-06 0.02   2.17E-03 0.30   2.38E-05 0.13   0.001 0.001 0.002 - 
cg17309464 ZNF565 19 5'UTR 36705192 1.96E-06 0.02   2.67E-07 0.02   7.98E-03 0.21   0.004 0.001 0.008 * 
cg04586332 [UPK3A] 22 -- 45659810 2.00E-06 0.02   5.60E-05 0.11   2.58E-04 0.15   0.006 0.001 0.012 - 
cg07032930 MRPL53 2 3'UTR 74699212 2.16E-06 0.03   1.38E-04 0.15   2.90E-05 0.13   0.002 0.001 0.003 - 
cg02430183 WNK2 9 1stExon 95947766 2.17E-06 0.03   2.84E-04 0.18   0.01 0.22   -0.004 -0.007 0 - 
cg06850509 -- 2 -- 96314847 2.22E-06 0.03   7.97E-03 0.40   3.15E-05 0.13   -0.005 -0.008 -0.003 - 
cg24114390 FAM133A X TSS1500 92928730 2.32E-06 0.03   2.23E-06 0.04   3.27E-03 0.19   0.003 0.001 0.006 * 
cg17822007 -- 3 -- 155463780 2.37E-06 0.03   1.36E-04 0.15   2.11E-05 0.13   0.007 0.003 0.011 - 
cg14030997 -- 9 -- 108420639 2.49E-06 0.03   2.42E-02 0.50   4.04E-05 0.13   -0.004 -0.007 -0.002 - 
cg14679558 -- 13 -- 21652153 2.70E-06 0.03   1.33E-03 0.27   8.21E-04 0.16   -0.002 -0.004 -0.001 - 
cg12637205 CYLD 16 5'UTR 50776628 2.71E-06 0.03   7.45E-04 0.24   4.64E-04 0.16   0.004 0.001 0.007 - 
cg09090582 CNPY1 7 5'UTR 155324691 2.77E-06 0.03   2.74E-04 0.18   2.57E-05 0.13   0.009 0.004 0.013 - 
cg03500617 -- 16 -- 74812570 2.86E-06 0.03   7.52E-04 0.24   1.85E-04 0.15   -0.005 -0.008 -0.002 - 
cg10493855 TTC7B 14 Body 91087586 2.89E-06 0.03   1.71E-04 0.16   1.64E-04 0.15   -0.008 -0.015 -0.002 - 
cg14945917 -- 4 -- 38145641 2.95E-06 0.03   1.72E-04 0.16   6.98E-05 0.13   -0.005 -0.008 -0.002 - 
cg16539640 CYFIP1 15 Body 22945028 2.98E-06 0.03   2.54E-03 0.31   5.58E-04 0.16   -0.002 -0.003 -0.001 - 
cg02564272 MAN1A1 6 Body 119507963 3.04E-06 0.03   1.66E-02 0.46   4.17E-03 0.19   -0.009 -0.018 -0.001 - 
cg18073471 PRDM8 4 5'UTR 81119198 3.24E-06 0.03   5.62E-04 0.22   3.23E-03 0.19   0.006 0.002 0.011 - 
12 
 
cg27568885 GCNT3 15 Body 59911449 3.45E-06 0.03   3.08E-08 0.01   3.13E-07 0.10   -0.003 -0.005 -0.002 * 
cg13468418 -- 4 -- 186048907 3.54E-06 0.03   1.04E-05 0.07   1.17E-04 0.14   0.003 0.002 0.004 - 
cg16560389 -- 10 -- 133318201 3.60E-06 0.03   4.31E-04 0.20   3.16E-05 0.13   -0.003 -0.006 -0.001 - 
cg16210526 -- 10 -- 134663864 3.71E-06 0.03   4.93E-05 0.11   3.62E-04 0.16   -0.004 -0.006 -0.001 - 
cg13521097 FERMT2 14 5'UTR 53417433 3.85E-06 0.03   8.06E-04 0.24   7.60E-04 0.16   0.002 0.001 0.003 - 
cg15799267 ALOX15B 17 5'UTR 7942406 4.08E-06 0.03   2.62E-03 0.32   5.26E-06 0.12   0.007 0.005 0.01 - 
cg19270277 CROCC 1 Body 17296995 4.10E-06 0.03   1.64E-04 0.15   2.29E-05 0.13   -0.006 -0.009 -0.003 - 
cg04375213 DCP1B 12 Body 2113435 4.12E-06 0.03   4.06E-06 0.05   7.33E-06 0.12   0.001 0.001 0.002 * 
cg13109184 LYST 1 -- 236029439 4.40E-06 0.03   4.95E-04 0.21   7.00E-03 0.20   0.005 0.001 0.01 - 
cg22902505 PRDM8 4 5'UTR 81119473 4.79E-06 0.04   4.50E-04 0.20   5.07E-05 0.13   0.009 0.005 0.015 - 
cg08614562 KIF1A 2 Body 241665572 5.13E-06 0.04   2.42E-03 0.31   9.33E-04 0.16   -0.004 -0.007 -0.001 - 
cg19864758 PCSK2 20 TSS1500 17206720 5.19E-06 0.04   2.90E-03 0.32   9.14E-05 0.13   0.003 0.001 0.005 - 
cg27063720 EP400NL 12 Body 132568987 5.23E-06 0.04   1.88E-05 0.08   8.97E-05 0.13   0.004 0.002 0.007 - 
cg24604043 SLC39A3 19 TSS1500 2740392 5.34E-06 0.04   4.17E-03 0.35   8.92E-03 0.21   0.004 0.001 0.008 - 
cg15136913 -- 10 -- 134893540 5.38E-06 0.04   9.07E-05 0.13   8.04E-05 0.13   -0.005 -0.009 -0.002 - 
cg19091677 HMGB2 4 TSS1500 174255518 5.44E-06 0.04   2.13E-04 0.17   7.46E-04 0.16   0.004 0.001 0.007 - 
cg10625723 -- 4 -- 6235503 5.50E-06 0.04   1.73E-02 0.47   2.08E-03 0.18   -0.002 -0.004 -0.001 - 
cg07821496 TDRKH 1 5'UTR 151762942 5.51E-06 0.04   5.99E-04 0.22   3.25E-05 0.13   0.005 0.002 0.007 - 
cg08294772 -- 8 -- 138135392 5.52E-06 0.04   9.92E-03 0.42   2.38E-05 0.13   0.007 0.004 0.01 - 
cg26309691 SCCPDH 1 Body 246887944 6.14E-06 0.04   5.21E-03 0.36   5.23E-04 0.16   0.003 0.001 0.005 - 
cg21074877 -- 14 -- 23481968 6.54E-06 0.04   1.16E-02 0.43   5.31E-04 0.16   -0.002 -0.003 -0.001 - 
cg19827167 MIR760 1 TSS200 94312206 6.56E-06 0.04   4.61E-03 0.35   5.63E-03 0.20   0.001 0 0.003 - 
cg27330720 FBXL20 17 TSS1500 37558981 6.67E-06 0.04   3.79E-05 0.10   6.64E-03 0.20   0.004 0.001 0.006 - 
cg05130304 C3orf23 3 TSS1500 44379503 6.72E-06 0.04   3.64E-04 0.20   9.69E-03 0.21   0.004 0 0.007 - 
cg26509269 -- 17 -- 34970306 6.89E-06 0.04   4.28E-04 0.20   1.41E-04 0.14   -0.004 -0.007 -0.002 - 
cg27496299 DNAJB6 7 Body 157171202 6.90E-06 0.04   2.07E-03 0.30   1.05E-04 0.13   -0.004 -0.007 -0.002 - 
cg02458885 PRDM8 4 5'UTR 81119249 6.93E-06 0.04   2.06E-04 0.17   2.33E-04 0.15   0.009 0.004 0.015 - 
cg21385432 EP400 12 Body 132512858 7.04E-06 0.04   4.71E-03 0.36   4.05E-04 0.16   -0.003 -0.006 -0.001 - 
cg06874656 NTM 11 TSS1500 131780353 7.10E-06 0.04   1.81E-03 0.29   5.98E-03 0.20   0.004 0.001 0.008 - 
cg21239691 GEMIN8 X TSS200 14048191 7.20E-06 0.04   7.54E-03 0.39   1.51E-05 0.13   0.006 0.003 0.01 - 
cg00895834 PRDM16 1 Body 3147966 7.20E-06 0.04   1.73E-04 0.16   3.73E-05 0.13   -0.005 -0.008 -0.003 - 
cg21473728 MYOM2 8 Body 2031651 7.42E-06 0.04   1.73E-03 0.29   1.27E-03 0.17   -0.006 -0.009 -0.001 - 
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cg10390589 SAE1 19 TSS200 47634047 7.64E-06 0.04   4.33E-03 0.35   0.01 0.23   0.002 0 0.004 - 
cg10246772 IGF1R 15 Body 99250916 7.90E-06 0.04   3.75E-02 0.54   4.68E-03 0.19   -0.004 -0.008 -0.001 - 
cg02514021 FLJ43663 7 Body 130791171 8.24E-06 0.04   6.20E-04 0.22   3.49E-03 0.19   0.006 0.001 0.012 - 
cg10609984 ZNF25 10 TSS200 38265593 8.43E-06 0.04   3.31E-05 0.10   1.49E-03 0.17   0.003 0.001 0.006 - 
cg25087154 IL1RAP 3 TSS1500 190231338 8.47E-06 0.04   9.19E-04 0.25   2.63E-03 0.18   0.005 0.001 0.008 - 
ch.11.150171F NUP98 11 Body 3739920 9.00E-06 0.04   4.58E-04 0.20   8.88E-04 0.16   0.005 0.002 0.008 - 
cg23284284 GIGYF2 2 TSS200 233561917 9.02E-06 0.04   6.68E-03 0.38   0.01 0.23   0.006 0.001 0.01 - 
cg01093285 PTPRN2 7 Body 157436506 9.38E-06 0.04   1.68E-03 0.29   4.52E-04 0.16   -0.006 -0.009 -0.002 - 
cg27632471 C20orf96 20 Body 259123 9.42E-06 0.04   1.43E-03 0.28   1.67E-03 0.17   -0.004 -0.007 -0.001 - 
cg12411309 SMUG1 12 5'UTR 54582659 9.51E-06 0.04   2.22E-03 0.30   3.65E-04 0.16   0.004 0.002 0.006 - 
cg17341361 TNRC18 7 Body 5414170 9.51E-06 0.04   1.58E-02 0.46   8.24E-04 0.16   -0.003 -0.004 -0.001 - 
cg07124687 -- 6 -- 28956332 9.71E-06 0.04   5.01E-05 0.11   1.57E-04 0.14   0.005 0.002 0.008 - 
cg12154976 RASGEF1C 5 5'UTR 179585198 9.84E-06 0.04   9.99E-05 0.13   1.30E-03 0.17   -0.006 -0.01 -0.002 - 
cg12398448 IGF1R 15 Body 99251461 9.87E-06 0.04   2.51E-03 0.31   3.70E-05 0.13   -0.007 -0.013 -0.003 - 
cg10462751 RIC8B 12 TSS200 107168330 1.03E-05 0.05   6.89E-04 0.23   9.50E-03 0.21   0.005 0.001 0.01 - 
cg04204072 THUMPD1 16 1stExon 20752857 1.04E-05 0.05   1.28E-02 0.44   1.61E-04 0.14   0.003 0.001 0.006 - 
cg10962490 GLIS1 1 5'UTR 54072456 1.05E-05 0.05   4.55E-04 0.20   1.31E-04 0.14   -0.004 -0.006 -0.001 - 
cg13653274 -- 10 -- 132632928 1.07E-05 0.05   1.18E-03 0.26   0.04 0.28   -0.006 -0.012 -0.001 - 
cg15472403 OSCAR 19 Body 54599455 1.09E-05 0.05   1.22E-03 0.27   8.18E-04 0.16   0.003 0.001 0.005 - 
cg00014152 WDR13 X Body 48457128 1.10E-05 0.05   2.40E-04 0.18   3.64E-04 0.16   -0.004 -0.007 -0.001 - 
cg25247351 HLA-DMB 6 1stExon 32908794 1.11E-05 0.05   1.46E-04 0.15   1.77E-03 0.17   0.003 0.001 0.005 - 
cg03156396 MSLN 16 Body 816177 1.13E-05 0.05   1.30E-05 0.07   4.79E-05 0.13   -0.006 -0.01 -0.002 - 
cg10650870 TNPO1 5 Body 72144764 1.15E-05 0.05   1.31E-03 0.27   1.76E-04 0.15   0.002 0.001 0.003 - 
cg01487433 CILP2 19 TSS200 19648987 1.15E-05 0.05   2.60E-04 0.18   1.78E-05 0.13   -0.002 -0.003 -0.001 - 
cg22533689 EPHA2 1 Body 16464479 1.16E-05 0.05   6.08E-03 0.37   0.01 0.22   -0.005 -0.009 -0.001 - 
cg13735965 ZNF616 19 TSS1500 52643487 1.18E-05 0.05   5.75E-03 0.37   5.42E-04 0.16   0.005 0.002 0.008 - 
cg07307426 DET1 15 5'UTR 89089587 1.18E-05 0.05   2.40E-04 0.18   0.01 0.23   0.004 0 0.008 - 
cg25002318 TRPV1 17 Body 3471868 1.20E-05 0.05   1.13E-03 0.26   5.74E-03 0.20   -0.005 -0.009 -0.001 - 
cg19554389 WNT5A 3 1stExon 55521134 1.20E-05 0.05   1.92E-03 0.30   0.01 0.23   0.003 0.001 0.005 - 
cg16953816 VPS37B 12 3'UTR 123349952 1.22E-05 0.05   7.14E-03 0.39   5.59E-04 0.16   -0.007 -0.01 -0.002 - 
cg14604000 C5orf13; NREP 5 TSS1500 111093875 1.24E-05 0.05   7.20E-06 0.06   2.23E-05 0.13   0.003 0.001 0.006 - 
cg11969467 MRPS14 1 TSS200 174992598 1.24E-05 0.05   3.45E-04 0.19   0.05 0.31   0.002 0 0.003 - 
14 
 
cg03998119 PTPN21 14 Body 88945315 1.25E-05 0.05   0.06 0.59   0.05 0.31   -0.005 -0.012 0 - 
cg03041046 SPRYD3 12 5'UTR 53473136 1.27E-05 0.05   1.10E-05 0.07   9.38E-04 0.16   0.005 0.001 0.009 - 
cg25051341 PRDM13 6 Body 100061307 1.30E-05 0.05   0.67 0.86   3.45E-03 0.19   0.002 0 0.005 - 
cg01407073 NAP1L1 12 TSS200 76478898 1.30E-05 0.05   9.16E-03 0.41   6.63E-04 0.16   0.004 0.001 0.007 - 
cg15874300 CRBN 3 Body 3221199 1.31E-05 0.05   1.30E-03 0.27   4.33E-04 0.16   0.003 0.001 0.004 - 
cg13144843 -- 3 -- 174158740 1.33E-05 0.05   9.94E-03 0.42   7.50E-04 0.16   0.003 0.001 0.004 - 
cg26163537 GRB10 7 TSS1500 50861592 1.37E-05 0.05   5.83E-05 0.11   4.75E-04 0.16   0.004 0.002 0.007 - 
cg20657691 RBM3 X TSS1500 48432562 1.38E-05 0.05   2.78E-04 0.18   0.01 0.22   0.006 0 0.012 - 
cg06616055 MUPCDH 11 Body 623756 1.42E-05 0.05   1.65E-04 0.16   3.76E-05 0.13   -0.007 -0.011 -0.003 - 
 
N.B. Genes with multiple significant probes are highlighted in blue. Standardized Beta estimates are used as a measure of effect size, where an effect of 0.10 is small 
effect, an effect of 0.24 is a medium effect, and an effect of 0.37 is a large effect. Values in grey represent non-significant estimates.    
aOriginal analysis: P-values and genome-wide corrected Q-values from the original epigenome-wide association analyses (i.e. correcting for age, sex and ethnicity)  
b SVA: P-values and genome-wide corrected Q-values after adjusting for the 11 surrogate variables identified via surrogate variable analysis.    
cWinsorizing: P-values  and genome-wide corrected Q-values  after winsorizing <5% and >95% values of score distribution in order to minimize the impact of 
outliers.   
dBootstrapping: Unstandardized betas and 95% Confidence Intervals (CIs) after bootrapping estimates 10,000 times.        
eHigh confidence associations (marked with *) are defined as having (i) a significant SVA q-value; (ii) a significant winsorized p-value; and (iii) bootstrapped CIs 
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OS6: Enriched biological processes for genes associated with epigenetic variation that is unique to each maltreatment type 






% p-value Genes 
 
Physical abuse 
          
1 regulation of cardiac muscle hypertrophy 3 24 13% 1.04E-12 RGS2;EDN1;ADRB1 
2 negative regulation of smooth muscle contraction 2 12 17% 9.01E-12 RGS2;ADRB1 
3 superoxide metabolic process 3 31 10% 6.38E-10 EDN1;MT3;PREX1 
4 metanephric nephron tubule development 2 15 13% 1.36E-09 CALB1;ACAT1 
5 oocyte maturation 2 16 13% 4.15E-09 BRCA2;REC8 
6 positive regulation of protein dephosphorylation 2 16 13% 4.90E-09 NELF;CALM1 
7 fucose metabolic process 2 16 13% 5.22E-09 B3GALTL;FUT5 
8 regulation of keratinocyte proliferation 2 17 12% 1.51E-08 CASK;PRKD1 
9 positive regulation of heart rate 2 18 11% 4.04E-08 EDN1;ADRB1 
10 male meiosis I 2 19 11% 1.03E-07 BRCA2;REC8 
11 regulation of urine volume 2 20 10% 2.19E-07 EDN1;ADRB1 
12 glycogen catabolic process 2 20 10% 2.32E-07 ADRB1;CALM1 
13 regulation of oxidoreductase activity 4 73 5% 3.26E-07 GLA;EDN1;CALM1;MT3 
14 negative regulation of oxidoreductase activity 2 21 10% 4.64E-07 GLA;MT3 
15 pyrimidine nucleoside triphosphate biosynthetic 
process 
2 21 10% 4.67E-07 RP2;TBPL1 
16 positive regulation of cation channel activity 2 23 9% 1.55E-06 ADRB1;CALM1 
16 
 
17 response to X-ray 2 24 8% 2.49E-06 ERCC8;BRCA2 
18 positive regulation of blood vessel endothelial cell 
migration 
2 25 8% 4.29E-06 FGF2;PRKD1 
19 fear response 2 27 7% 9.95E-06 ADRB1;GABRA5 
20 regulation of wound healing 4 94 4% 1.30E-05 CASK;GP5;FGF2;EDN1 
21 negative regulation of stress-activated protein 
kinase signaling cascade 
2 29 7% 2.48E-05 HDAC3;MPP2 
22 regulation of glycoprotein biosynthetic process 2 29 7% 2.54E-05 ACAT1;MT3 
23 brown fat cell differentiation 2 30 7% 2.83E-05 RGS2;ADRB1 
24 positive regulation of osteoblast differentiation 3 62 5% 3.17E-05 BMPR1B;FGF2;PRKD1 
25 positive regulation of DNA repair 2 30 7% 3.31E-05 ERCC8;MPP2 
26 protein kinase B signaling 2 30 7% 3.43E-05 RPS6KB2;MT3 
27 negative regulation of endocytosis 2 30 7% 3.43E-05 PRKD1;PRTN3 
28 eye photoreceptor cell development 2 31 6% 4.95E-05 CRB1;BHLHE23 
29 activation of adenylate cyclase activity 2 33 6% 7.98E-05 ADRB1;CALM1 
30 positive regulation of muscle contraction 2 33 6% 9.09E-05 RGS2;EDN1 
31 regulation of cardiac muscle contraction 3 70 4% 9.79E-05 RGS2;ADRB1;CALM1 
32 regulation of cytokinesis 2 35 6% 1.49E-04 BRCA2;CALM1 
33 regulation of multicellular organism growth 3 81 4% 4.75E-04 HDAC3;ADRB1;GDF5 
34 negative regulation of purine nucleotide metabolic 
process 
2 42 5% 6.16E-04 CPEB2;EDN1 
35 connective tissue development 5 198 3% 6.26E-04 BMPR1B;FGF2;EDN1;ACAT1;GDF5 
17 
 
36 regulation of phospholipase activity 3 87 3% 7.38E-04 RGS2;FGF2;CALM1 
37 regulation of cell development 10 590 2% 8.27E-04 FGF2;EDN1;NELF;ADRB1;LRRC4C;PRKD1;MT3;PREX1;BHLHE23;
GDF5 
38 regulation of G-protein coupled receptor protein 
signaling pathway 
4 140 3% 8.33E-04 RGS2;EDN1;CALM1;KLK5 
39 dorsal/ventral pattern formation 3 94 3% 1.37E-03 DISP1;BMPR1B;EDN1 
40 negative regulation of epithelial cell proliferation 3 96 3% 1.62E-03 CASK;BRCA2;GDF5 
41 cellular response to abiotic stimulus 5 223 2% 2.26E-03 TNFRSF8;TNFRSF10A;NELF;SNCG;CALM1 
42 double-strand break repair via homologous 
recombination 
2 52 4% 2.82E-03 BRCA2;REC8 
43 regulation of pH 2 52 4% 2.89E-03 EDN1;ATP5B 
44 inositol phosphate metabolic process 2 56 4% 4.02E-03 FGF2;CALM1 
45 regulation of cell death 16 1284 1% 4.75E-03 MST4;TNFRSF8;NLRP3;BMPR1B;FGF2;HDAC3;IL20RA;EDN1;NEL; 
ADRB1;PRKD1;GABRA5;RNPS1;MT3;BHLHE23;GDF5 
46 negative regulation of NF-kappaB transcription 
factor activity 
2 62 3% 7.65E-03 ZCCHC11;NLRP3 
Physical neglect           
1 regulation of cholesterol efflux 4 17 24% 2.91E-11 ABCA1;LRP1;CETP;APOE 
2 negative regulation of multicellular organism 
growth 
3 12 25% 2.12E-09 ANKRD26;ATXN2;BBS2 
3 negative regulation of endothelial cell migration 5 31 16% 2.94E-09 CXCL13;ACVRL1;APOH;PTPRM;APOE 
4 mitotic G2 DNA damage checkpoint 3 14 21% 4.08E-08 CDC2;CDK1;C10orf90 
5 spermatid nucleus differentiation 3 15 20% 1.37E-07 KDM3A;HIST1H2BA;DMRTC2 
18 
 
6 negative regulation of endothelial cell proliferation 4 26 15% 2.25E-07 ACVRL1;APOH;PTPRM;APOE 
7 receptor-mediated endocytosis 9 113 8% 1.03E-06 FCHO2;LRP12;LRP1;NEDD4;CETP;COLEC12;DNM2;LDLR;APOE 
8 endocytosis 19 372 5% 2.09E-06 CDC42SE1;DNM3;STON1-
GTF2A1L;ELMOD2;FCHO2;LRP12;DENND1A;ABCA1;GAPVD1;EEA
1;LRP1;NEDD4;CETP;DLG4;MRC2;COLEC12;DNM2;LDLR;APOE 
9 phospholipid transport 5 45 11% 2.72E-06 ATP11B;ABCA1;CETP;LDLR;APOE 
10 cerebellar cortex development 5 47 11% 4.86E-06 HSPA5;MDK;ATXN2;GLI1;NEUROD2 
11 microtubule bundle formation 4 32 13% 5.31E-06 KIF20A;MAP1B;BBS2;MARK4 
12 rRNA transcription 3 20 15% 8.54E-06 GTF3C3;GTF3A;CD3EAP 
13 intracellular pH reduction 3 20 15% 8.70E-06 CLIC4;CLCN3;AQP11 
14 G-protein coupled glutamate receptor signaling 
pathway 
2 10 20% 1.30E-05 GRM8;GRM5 
15 negative regulation of receptor-mediated 
endocytosis 
2 10 20% 1.34E-05 ATXN2;DLG4 
16 synaptic vesicle endocytosis 3 21 14% 1.51E-05 DENND1A;EEA1;DLG4 
17 polyamine metabolic process 3 21 14% 1.57E-05 ADI1;AZIN1;MTAP 
18 response to copper ion 3 22 14% 2.71E-05 ABP1;CDC2;CDK1 
19 regulation of endothelial cell chemotaxis 2 11 18% 3.66E-05 CXCL13;HSPB1 
20 receptor catabolic process 2 11 18% 3.69E-05 GPRASP1;NEDD4 
21 regulation of platelet-derived growth factor receptor 
signaling pathway 
2 11 18% 3.70E-05 LRP1;F7 
19 
 
22 peptidyl-glutamic acid carboxylation 2 11 18% 3.76E-05 F7;F10 
23 protein localization to kinetochore 2 11 18% 3.77E-05 CDC2;CDK1 
24 negative regulation of muscle cell apoptotic process 3 23 13% 4.24E-05 BAG3;NACA;APOH 




26 regulation of Cdc42 protein signal transduction 3 24 13% 6.99E-05 FGD1;ABCA1;APOE 
27 cellular response to inorganic substance 7 99 7% 7.71E-05 CLIC4;ABP1;ASPH;FOXO1;MT1L;CES1;NEUROD2 
28 positive regulation of skeletal muscle tissue 
development 
2 12 17% 8.57E-05 CDON;NACA 
29 mitochondrial calcium ion homeostasis 2 12 17% 8.79E-05 CCDC90A;ATP2A1 
30 histone H3-K4 trimethylation 2 12 17% 8.80E-05 MLL2;ARID4A 
31 methionine biosynthetic process 2 12 17% 8.81E-05 ADI1;MTAP 
32 cell migration involved in gastrulation 2 12 17% 8.85E-05 FOXH1;MESP2 
33 lipoprotein metabolic process 7 100 7% 8.85E-05 HHAT;ABCA1;LRP1;CETP;MPPE1;LDLR;APOE 
34 negative regulation of smoothened signaling 
pathway 
3 25 12% 1.02E-04 GPR161;CHRD;GLIS2 
35 transcription from RNA polymerase III promoter 4 42 10% 1.44E-04 GTF3C3;POLR3G;CRCP;GTF3A 





OS7: Enriched biological processes for genes associated with epigenetic variation that is shared across maltreatment types (physical abuse, sexual abuse and neglect) 
GO Pathway  N genes 
in input 
list  
 Totan N in 
pathway 
% p-value Genes 
1 regulation of 
nervous system 
development 












2 regulation of 
growth 

















































































5 neurological system 
process 





































7 regulation of 
mesenchymal cell 
apoptotic process 
8 13 61.54 2.85E-07 POU3F4;MSX1;HOXA13;PAX2;WT1;HNF1B;BMP7;TBX1 
8 regulation of glial 
cell proliferation 
9 15 60.00 4.00E-07 SKI;SOX11;ETV5;NOTCH1;ASCL2;RNF10;PRKCH;ADCYAP1;TSPO 
26 
 















11 muscle structure 
development 







12 neural tube closure 26 76 34.21 7.09E-06 VANGL2;ENAH;SKI;ZEB2;WNT5A;IFT122;SHROOM3;SFRP2;T;TFAP2A;COBL;SCRIB;DLC1;PTCH1;P
AX2;APAF1;KDM2B;LRP6;PRICKLE1;ZIC5;RGMA;TSC2;TGIF1;VASP;PLXNB2;CELSR1 
13 positive regulation 
of cell-cell adhesion 
mediated by 
integrin 
6 10 60.00 8.39E-06 WNT3A;WNT5A;PODXL;FOXA1;FAM38A;FOXA2 
27 
 




10 22 45.45 1.01E-05 DLG3;VANGL2;ERBB2IP;SCRIB;ANK1;CDX2;FOXF1;DLG4;FOXJ1;LAMA1 
15 establishment or 
maintenance of 
bipolar cell polarity 
10 22 45.45 1.01E-05 DLG3;VANGL2;ERBB2IP;SCRIB;ANK1;CDX2;FOXF1;DLG4;FOXJ1;LAMA1 
16 actin filament-
based process 








17 negative regulation 
of ossification 
12 32 37.50 2.33E-05 BCOR;AHSG;SMURF1;PTK2B;NOTCH1;LTBP3;CALCA;LRP4;NFE2;LRP10;GREM1;BCL2 












20 regulation of 
neurological system 
process 






21 positive regulation 
of muscle cell 
differentiation 
20 61 32.79 2.61E-05 WNT3A;CTNNA2;CYP26B1;SHOX2;FOXP1;IGFBP3;NRG1;MYF6;MEG3;SETD3;PIAS1;GREM1;ZFHX3;
CDH15;CDH3;MAP2K6;BCL2;TCF3;TBX1;MAPK12 
22 endothelial cell 
migration 
16 49 32.65 2.98E-05 AMOT;PLEKHG5;ROBO1;GPX1;GPLD1;SRF;PTK2B;PTK2;LOXL2;ITGB1;PTEN;APOA1;CALCA;GRE
M1;CDH13;TNFSF12 
23 regulation of lipid 
kinase activity 
13 35 37.14 3.22E-05 VAV3;IRS1;FGFR3;PTK2B;PTK2;VAV2;DAB2IP;CCKBR;CD81;RB1;FLT3;RBL1;PIK3IP1 
24 regulation of 
gastrulation 
11 27 40.74 3.82E-05 WNT3A;IL1RN;SFRP2;SOX17;DKK1;APOA1;ODZ4;MAP2K5;HNF1B;TGIF1;FOXA2 




39 160 24.38 4.42E-05 PTPRU;IGFBP5;IL1RN;HYAL2;SFRP2;MCC;CSNK2B;SRF;PKHD1;IGFBP3;STK3;TRIB1;DLC1;TP53IN
P1;NOTCH1;DAB2IP;GDF2;PTEN;GTPBP4;MUC2;IFITM1;LRP1;CDKN1B;STK24;ACTN1;NR2F2;THB
S1;TPM1;MAP2K5;GREM1;ABR;STAT3;ALOX15B;HDAC5;FLCN;BCL2;HAS1;ADARB1;NF2 
26 base-excision repair  
AP site formation 
5 10 50.00 5.66E-05 MID1;CCNO;SMUG1;MPG;MED1 
27 negative regulation 
of growth 




28 negative regulation 
of BMP signaling 
pathway 
14 37 37.84 7.03E-05 SKI;TRIM33;WNT5A;SFRP2;SMURF1;HIPK2;SOSTDC1;NOTCH1;TCF7L2;HTRA1;DKK1;SMAD6;FBN1
;GREM1 
29 regulation of 
embryonic 
development 







10 27 37.04 7.40E-05 VPS54;TNNC1;ITPR1;HIPK2;TNNT3;TNNI2;ATP8A2;HSP90AA1;CACNA1A;TNNT1 
31 musculoskeletal 
movement 
10 27 37.04 7.40E-05 VPS54;TNNC1;ITPR1;HIPK2;TNNT3;TNNI2;ATP8A2;HSP90AA1;CACNA1A;TNNT1 
32 hindbrain 
development 
37 130 28.46 8.07E-05 MECP2;DAB1;GNPAT;LMX1A;SDF4;CTNNA2;GLI2;NRXN1;OTX1;SERPINE2;EN1;NR2C2;ATG7;OGD
H;DLC1;KNDC1;ITGB1;PAX6;CEND1;LHX5;KDM2B;LRP6;ULK1;SMAD9;SSTR1;RORA;SEZ6L2;MYH1
0;HOXB3;SEZ6;HNF1B;BCL2;CACNA1A;PTPRS;SMARCA4;FOXA2;PCNT 
33 positive regulation 
of skeletal muscle 
tissue development 
6 12 50.00 9.39E-05 SHOX2;HMGCR;SOX17;USP2;MEG3;BCL2 
34 hair cycle process 22 79 27.85 1.06E-04 EDA;VANGL2;IGFBP5;WNT10A;PDGFA;SOSTDC1;NOTCH1;DKK1;ALX4;BARX2;LRP4;RELA;HOXC1
3;SOX21;AKT1;LRP10;BCL2;ERCC2;TGM3;LAMA5;TFAP2C;CELSR1 
35 hair follicle 
development 
22 79 27.85 1.06E-04 EDA;VANGL2;IGFBP5;WNT10A;PDGFA;SOSTDC1;NOTCH1;DKK1;ALX4;BARX2;LRP4;RELA;HOXC1
3;SOX21;AKT1;LRP10;BCL2;ERCC2;TGM3;LAMA5;TFAP2C;CELSR1 
36 molting cycle 
process 
22 79 27.85 1.06E-04 EDA;VANGL2;IGFBP5;WNT10A;PDGFA;SOSTDC1;NOTCH1;DKK1;ALX4;BARX2;LRP4;RELA;HOXC1
3;SOX21;AKT1;LRP10;BCL2;ERCC2;TGM3;LAMA5;TFAP2C;CELSR1 
37 establishment of 
nucleus localization 
6 11 54.55 1.08E-04 SYNE1;PTK2;SLIT1;SPTBN5;MYH10;NTN1 
38 viral entry into host 
cell 
6 13 46.15 1.36E-04 HYAL2;ZNF639;WWP1;PVRL1;CD81;WWP2 





40 mammary gland 
morphogenesis 




41 activation of 
MAPK activity 
31 132 23.48 1.62E-04 MAP3K7IP3;IKBKG;IRAK1;SHC1;KIAA1804;ZAK;PROK2;WNT5A;MAPK10;C1QTNF2;DAXX;GRM4;M
AP3K5;GRM1;GCK;NOD1;DAB2IP;DRD4;CD81;MAP4K2;FRS2;PXN;THBS1;PTPLAD1;MAP2K5;MAP
K8IP3;MAP2K6;MAP4K1;INSR;LPAR2;MAP3K7IP1 











43 negative regulation 
of cell fate 
commitment 
6 13 46.15 2.01E-04 WNT3A;SFRP2;SOSTDC1;SOX17;NKX6-2;DKK1 
44 multicellular 
organismal 
response to stress 





7 16 43.75 2.16E-04 SLC6A3;DAGLB;CHAT;GAD2;DAGLA;ALDH2;COMT 
46 proximal/distal 
pattern formation 
12 34 35.29 2.17E-04 GLI2;HOXD11;EN1;HOXD9;CYP26B1;IRX2;GLI3;HOXA9;LRP4;HOXC11;LRP10;GREM1 
47 regulation of 
skeletal muscle 
tissue development 
20 61 32.79 2.96E-04 TSC22D3;MBNL3;HDAC4;ACVR1;CYP26B1;SHOX2;NR1D2;HMGCR;IGFBP3;SOX17;NOTCH1;TCF7L2
;DKK1;USP2;PRICKLE1;MEG3;ZFHX3;HDAC5;BCL2;TBX1 
48 primitive streak 
formation 
5 10 50.00 3.04E-04 WNT5A;T;SRF;LRP6;FOXA2 








50 regulation of sister 
chromatid cohesion 
5 11 45.45 3.68E-04 NSMCE2;CDCA5;ESPL1;RB1;AXIN2 








12 35 34.29 3.88E-04 EPAS1;HMGCR;T;SRF;NRG1;NOTCH1;TCF7L2;HINFP;RB1;ASB2;GREM1;MAPK12 
53 negative regulation 
of cell motility 
36 156 23.08 4.10E-04 PTPRU;IGFBP5;IL1RN;HYAL2;SFRP2;MCC;CSNK2B;SRF;IGFBP3;STK3;TRIB1;DLC1;TP53INP1;NOT
CH1;DAB2IP;GDF2;PTEN;GTPBP4;MUC2;IFITM1;LRP1;STK24;NR2F2;THBS1;TPM1;MAP2K5;GREM
1;ABR;STAT3;ALOX15B;HDAC5;FLCN;BCL2;HAS1;ADARB1;NF2 





5 11 45.45 4.25E-04 PDGFC;ADRB2;NRG1;NRG3;GREM1 
55 response to growth 
factor 











56 negative regulation 
of cell-cell adhesion 










58 asymmetric protein 
localization 
7 17 41.18 5.29E-04 SHROOM2;VANGL2;MAL;SHROOM3;ERBB2IP;SCRIB;CELSR1 
59 positive regulation 
of lipid biosynthetic 
process 
14 47 29.79 5.39E-04 MID1IP1;CREB1;ACSL6;GPLD1;ZP3;SORBS1;SIRT4;HTR2A;AKT1;IGF1R;SREBF1;NR1D1;APC2;ABC
G1 
60 retina development 
in camera-type eye 
29 113 25.66 5.54E-04 NPHP4;SKI;GNB1;MERTK;CNGA3;PDE6B;LPCAT1;GRM6;PDE6A;TFAP2A;HIPK2;TSPAN12;CHD7;P
AX2;LRP5;PVRL1;DRD4;TUB;RRM1;LRP6;MDM1;RPGRIP1;VSX2;MEGF11;MYH10;MED1;TGIF1;LA
MA1;SMARCA4 
61 cell-type specific 
apoptotic process 
22 83 26.51 5.72E-04 RYR2;NGF;GNB1;HTT;POU4F3;RPS6KA2;TNFRSF21;GLI3;STK3;MYC;GDF6;DAB2IP;APAF1;RB1;JA
G2;HSP90AA1;AKT1;AATK;BCL2;PLK5P;PIGT;TBX1 
62 positive regulation 
of B cell 
proliferation 
11 38 28.95 5.88E-04 IL13RA1;WNT3A;VAV3;PELI1;MAL;BCL6;CDKN1A;CARD11;BCL2;TCF3;NFATC2 
63 oligodendrocyte 
development 
12 37 32.43 7.14E-04 CNTN2;SOX11;HDAC11;FGFR3;GSN;NKX6-2;TCF7L2;ZNF488;PTEN;ODZ4;EIF2B1;ERCC2 
64 negative regulation 
of smoothened 
signaling pathway 
9 25 36.00 7.43E-04 REN;SERPINE2;IFT122;FGFR3;GLI3;PTCH1;RB1;KIF7;SALL3 
33 
 
65 extracellular matrix 
organization 






66 ventral spinal cord 
interneuron 
specification 
6 11 54.55 7.85E-04 GLI2;NKX6-1;GLI3;NKX6-2;PAX6;DBX1 
67 cell fate 
specification 
involved in pattern 
specification 
6 11 54.55 7.85E-04 GLI2;NKX6-1;GLI3;NKX6-2;PAX6;DBX1 
68 neural tube 
patterning 
12 34 35.29 9.64E-04 WNT3A;GLI2;EN1;IFT122;GLI3;SOX17;PTCH1;PAX6;KDM2B;LRP6;FOXA1;FOXA2 
69 receptor clustering 11 28 39.29 9.93E-04 FLNA;AGRN;NRXN1;ETV5;IFT122;DOK7;SYNGAP1;LRP4;LRP10;DLG4;CACNA1A 
70 temperature 
homeostasis 
8 27 29.63 1.16E-03 IL1RN;GPX1;ADRB2;HTR2A;GPX2;FTO;NR1D1;STAT3 
71 establishment of 
mitotic spindle 
localization 
6 16 37.50 1.20E-03 ARHGEF2;HTT;INSC;ESPL1;NUSAP1;NDE1 
72 intrinsic apoptotic 
signaling pathway 
in response to 
oxidative stress 
6 17 35.29 1.32E-03 GPX1;MAP3K5;STK3;STK24;UACA;BCL2 
34 
 
73 negative regulation 
of cell proliferation 








74 negative regulation 
of canonical Wnt 
signaling pathway 
23 91 25.27 1.46E-03 FAM123B;WWTR1;SIAH2;WNT5A;DKK2;SFRP2;MCC;ANKRD6;GLI3;SOSTDC1;STK3;SOX17;NOTCH1
;DAB2IP;ROR2;TCF7L2;DKK1;LRP4;PRICKLE1;LRP10;GREM1;AXIN2;APC2 




6 14 42.86 1.74E-03 IRS1;C1QTNF2;GCK;SORBS1;AKT1;INSR 
76 activation of 
MAPKKK activity 
5 13 38.46 1.81E-03 GCK;DAB2IP;MAP4K2;MAP4K1;MAP3K7IP1 





8 23 34.78 1.81E-03 NTRK1;SERPINE2;SLC12A2;FYN;GRIN2B;HTR2A;ACCN1;TMC2 
78 cellular protein 
complex assembly 




79 neural precursor 
cell proliferation 











5 12 41.67 1.91E-03 ACVR1;STK3;NRG1;SOX17;NOTCH1 
82 protein 
polyubiquitination 
34 174 19.54 1.91E-03 UBE2A;HUWE1;PSMB2;PELI1;PSMD14;PSME4;RNF168;FBXW11;PSMB9;PARK2;PSMB1;SMURF1;U
BE3C;RNF216;TNKS;TRAF2;UBE2D1;TNKS2;PSMD9;CHFR;ANAPC5;CDC16;ASB2;WWP2;MGRN1;PS
MB10;CDC27;NEDD4L;BCL2;UBE2S;APC2;FZR1;UBE2V1;PSMF1 
83 axis elongation 9 25 36.00 2.07E-03 VANGL2;WNT3A;WNT5A;SFRP2;RDH10;LRP6;MED1;TRIM28;TFAP2C 
84 negative regulation 
of cysteine-type 
endopeptidase 
activity involved in 
apoptotic process 
16 66 24.24 2.29E-03 RPS6KA3;DDX3X;HBXIP;MAL;SIAH2;PAK2;GPX1;SFRP2;FNIP1;DNAJB6;INTS1;PAX2;PRDX5;AKT1;
THBS1;MAP2K5 
85 epithelial cell fate 
commitment 
7 17 41.18 2.35E-03 ARX;ACVR1;FGFR3;HOXA13;NOTCH1;JAG2;NR2F2 









87 negative regulation 
of muscle cell 
apoptotic process 
8 23 34.78 2.95E-03 SFRP2;HMGCR;PTK2B;NRG1;LRP6;IGF1R;ADCYAP1;BMP7 
88 phospholipid efflux 4 11 36.36 3.55E-03 APOA1;APC2;ABCA7;ABCG1 
89 regulation of energy 
homeostasis 
4 10 40.00 4.31E-03 SGIP1;PASK;NR1D2;FLCN 
36 
 
90 cellular cation 
homeostasis 





91 regulation of 
sodium ion 
transport 
14 51 27.45 4.85E-03 DMD;SERPINE2;MAGI1;CAMK2D;ADRB2;UTRN;CNKSR3;WNK2;DRD4;TESC;FGF14;AKT1;NEDD4L;
SIK1 
92 negative regulation 
of 
phosphatidylinosito
l 3-kinase signaling 




5 14 35.71 4.96E-03 PHF13;NCAPH;CDCA5;NCAPD2;NUSAP1 
94 negative regulation 
of reproductive 
process 
8 28 28.57 5.76E-03 PRDX4;WNT5A;ZP3;SF1;WT1;CDKN1B;BMP7;TPST2 
95 positive regulation 
by host of viral 
transcription 
4 11 36.36 7.12E-03 ZNF639;SNW1;SMARCA4;EP300 
96 beta-amyloid 
metabolic process 
4 12 33.33 7.15E-03 REN;MME;TMED10;UNC13A 
97 protein 
homotrimerization 
5 15 33.33 8.74E-03 SKI;TRPM8;SKIL;TRAF2;HSF4 
98 transepithelial 
transport 




9 37 24.32 9.76E-03 UGP2;MAT2B;NDST1;GCK;EXT1;PPP1R3C;AKT1;GLT25D1;HAS1 
100 citrulline metabolic 
process 
4 11 36.36 1.44E-02 DDAH1;HTT;DDAH2;ALDH18A1 
 
 
